

Continue

Hypogonadotropic hypogonadism treatment guidelines

Skip Nav Target PDF Split view article content figures & complementary audio video tables Data initiation and maintenance of reproductive ability in humans depends on the pulsatile secretion of the hypothalamosic hormone GnRH. Congenital hypogonutropic (CHH) is a rare disorder that has been left out of the failure of the normal episodic GnRH secretion, leading to sexual maturity and delayed fertility. CHH can be associated with a missing sense of smell, either kalman syndrome, or with other abnormalities. CHH is characterized by rich genetic heterogeneity, with mutations >30 genes identified so far that work alone or in combination. CHH can be challenging to diagnose, especially in early adolescence where the clinical picture reflects that of a constitutional setback of growth and sexual maturity. Timely diagnosis and treatment will induce puberty, leading to improved sexual, bone, metabolic, and psychological health. In most cases, patients require lifelong care, yet a prominent portion of male patients (~10% to 20%) and male patients (~10% to 20%). Demonstrate spontaneous recovery of their reproductive function. Finally, infertility can be induced with pulsatile GnRH treatment or gonadotrophin regimens in most patients. In conclusion, this review is a comprehensive synthesis of the current literature available regarding diagnosis, patient management, and genetic underpinnings of CHH relative to normal reproductive development. Minipuberty is an important window to assess the activity of the hypothalamus-pituitary-pituitary-pituitary-pituitary gland axis, especially male newborns with cryptorchidism and/or micropenis, to diagnose neonatal congenital hypogonadotropic hypogonadotropic hypogonism (CHH)today, It is difficult to differentiate CHH from the constitutional delay of growth and sexual maturity (CDGP) in early adolescence, as these two conditions have almost identical clinical presentations and biochemical profiles while waiting for the development of innovative biomarkers, testicular volume and Serum levels in cycle B may be the most reliable parameters to date to differentiate CHH from CDGPGiven in chh's complex genetics, Including ulogganism, reduced permeability, and variable expressiveness, defining a clear genetic diagnosis for each patient is often discouraging effective treatments to induce secondary sexual characteristics in both sexes; However, the role of gonadotrophin therapy during neonatal and adolescent periods remains unclear in patients with CHH and can often be successfully treated with a combination of gonadotrophins or Pulsatile GnRH, although patients with the most severe form of GnRH deficiency may benefit from a treatment coefficient with FSHPuberty and is one of the most prominent developmental processes after birth in humans. It is accompanied by the acquisition of secondary sexual characteristics, the onset of fertility, achieving adult height and impulsive psychosocial changes Puberty is initiated by the reawakening of the pituitary hypothalamus-pituitary-pituitary gland (HPG) axis following relative remission during childhood (2). The secretion of Pulsatile of GnRH by special neurons in the hypothalamus stimulates the release of FSH and LH by the pituitary, which in turn stimulate steroid gametogenesis in glands. In particular, puberty begins two periods of HPG axis activity: fetal life and infancy (mini-puberty). Puberty timing varies widely in population, and 50% to 80% of variance is genetically determined (3-5). Delayed puberty is defined as a delay of early puberty or progression >2 SD compared to the say population (6). Constitutional delay of growth and sexual maturity (CDGP) is the most common cause of delayed sexual maturity (2% in the general population) and is associated with transient deficiency in GnRH. At CDGP, adolescence eventually begins and is spontaneously perfect. In contrast, hypogonadotropic congenital hypogonadotrophic (CHH) is a rare genetic disease caused by GnRH deficiency. This sterility is medically treatable, and in fact CHH is one of the few treatable causes of infertility in men. When CHH is associated with anesmia, it will also be described as Kalman Syndrome (KS). Considerable differences exist in terminology surrounding the permanent forms of GnRH deficiency in humans, with idiopathic hypogonadotropiide (IHH), isolated GnRH deficiency, and CHH used almost intermittently. IHH was the first terminology to appear in print (8); However, idiopathic is usually reserved for diseases that appear spontaneously or whose cause is unknown (9). Several molecular etiologies have since been described as the basis for this disorder, resulting in the least frequent use of IHH. An isolated shortage of GnRH was first reported in literature in 1986 (10) and is still widely used in North America. However, the disorder can be due to GnRH receptor mutations, resulting in a state of GnRH resistance rather than deficiency. CHH was first used in 1980 (11). Although the diagnosis is often made during adolescence or afterwards, the disease is mainly due to developmental defects (i.e., defects in GnRH neuron migration or maturation of the GnRH neural network) and is often associated with congenital traits. The term CHH is commonly used, especially in Europe, and is used in this review. In this review, we describe the spectrum of CHH clinical presentations, diagnostic assessments including the challenge of Biedil CHH CDGP, advances in genetic diagnosis and treatment for CHH, as well as the consequences of delay in diagnosis. Finally, we discuss therapeutic possibilities from different perspectives. To achieve these goals, we also look at hpg's normal physiology Fetal development of hpg axis active HPG axis undergoing midgestational but is trembling towards range (12). This restraint is removed after birth, leading to a reactivation of the axis and an increase in gonadotropin (mini-polyesteria) levels. Most GnRH secretion neurons are located in the arcuate nucleus and preoptic area of the hypothalamus (13). GnRH neurons are an unusual neural population, as they originate outside the central nervous system in olfactory phycode, and follow a complex migration path to reach their final destination in the hypothalamus (14, 15). The complex developmental process of GnRH neurons has evolved in both murine and human genetic studies (16-18). The GnRH neuron fate specification occurs from human parent cells in the olfactory placod during pregnancy week (GW) 5 in humans, and days 9.5 to 11 in mice (19). Then, GnRH neurons begin their migration from the nasal placode, following axon guidance of vomeronasal nerve (VNN) and olfactory nerve until they cross the nasal mesenchyme and cribriform plate. Then, GnRH neurons follow the guidance of the VNN thymostic branch, reaching the main brain. Hence, General's neurons detisted from the VNN axons to reach their final destination in the arch nucleus and pre-optical region of the hypothalamus. Then, they extend their axons to the median symbol, reaching the illuminated blood-brain dose of the hypothalamo-cerebral gateway vessels. On day 16 in ~15 weeks of pregnancy in humans, GnRH is identified in the hypothalamus and the neural system GnRH is largely completed (18, 20). Recently, studies of GnRH ontogeny in mice and humans using the innovative technique of cleaning 3DISCO optical tissues reveal the detailed dynamics of ongeny neuron GnRH and migration from the nasal cell to the brain forward. In particular, the number of GnRH neurons in the human fetal brain is much higher (~10,000) than earlier (18). LH is detected in the human anterior pituitary gland by GW 9 (21) and is released into circulation by GW 12 (22-24). The exact timing when secreting the hypothalamic gonadotrophin will come under the control of hypothalamus GnRH is unclear. In encephalom embryos without hypothalamus, the development of the cerebral cortex is normal until GW 17 to 18 before it curves, suggesting that hypothalamus pinging is required for maintenance of the condotrophs at this time (25). Gondotropin levels of embryo serum peak in midgesthan in both sexes and fall in the near term (26). This decrease in bodiestrophins is likely due to the negative feedback brokered by increased placent estrogen (12). However, limited data exists on hypothalamus-vasodilation function in human embryos after GW 22 (26). Females typically exhibit high levels in the FSH and LH cycle in the range of post-menopausal women, which Much higher than in male embryos (22, 23, 26-29). In the near term, circulating gonadotrophin levels decrease. The latter is thought to be linked to the rise of placent estrogens and progesterone, the acquisition of nuclear receptors and sex steroids by pituitary gonadotrophic cells, and pituitary gland feedback (22-24, 28, 30). The differentiation of an antennae into testicles and ovaries occurs between GW 5 and 7. This is a complex process involving a critical role of the SRY gene on the Y chromosome for males. During GW 8, Sertoli cells differentiated in seminiferous tubes to start producing antimaller hormone (AMH) under the contol of SOX9, which leads to a regression of Müllerian canals (31). Placental human chorionic gonadotrophin (hCG) during the first trimester and then embryonic cerebral LH from midgestation regulate Leydig cell differentiation to produce testosterone (T) from fetal Leydig cells (32), which is required for the fetal masculinity. T is necessary for the development of male internal genitalia, while dihidrostosterone produced by the enzyme 5-α reductase 2 (SRD5A2) causes prostate, penis and scrotum formation. Up to midgestation, T production is driven by placental hCG rather than by the secretion of LH induced GnRH by the fetus. This is consistent with the absence of genital differentiation defects in CHH. However, during the third period of pregnancy pearl growth and decreased inguinoscrotal testicles occur, brokered in part by T stimulated by the secretion of LH induced GnRH [tested in judges. (33) and 34)] In females, they also develop in the absence of the Y chromosome. In addition, the differentiation of internal or external genitalia occurs regardless of the ovaries. In the absence of AMH, the Müllerian tubes will develop into fallots, uterus, and part of the vagina. In humans, ancient follicles develop fetal ovation around GW 15 (36) and are independent gonadotrophin. At this point, the amount of fetal ovarian steroid production appears to be minimal compared to high placental estrogen production (37). Fetal reproductive development: Implications for CHH phenotypes disruption of the complex ontogeny of GnRH neurons and olfactory system can lead to GnRH deficiency, in severe cases, CHH with or without anosmia. However, during the first trimester of pregnancy, which is critical for sexual differentiation, the GnRH neural system is not purposeful. As a result, the differentiation of genitals in CHH is normal. Conversely, during late pregnancy the secretion of LH induced GnRH stimulates further growth in fusion and decreased testicles. Therefore, a higher incidence of micropenalis and crypto-recidism is met with CHH [reviewed in Ref. (34)]. Presentation of CHH's CHH clinical presentation during a normal minipuberty mini-puberty within minutes of birth, a short LH surge after birth leads to an increase in T-levels during the first day of life, which then subsides (38). After the first week after birth, as serum placenta estrogen levels decreased, increased pulsatile GnRH secretion (39) leads to high gonadotrophins and sex steroid levels in both sexes, with peak levels observed at age 1 to 3 months (minipuberty) (40-44). During this time, FSH levels are higher in girls, and LH levels are dominant in boys (43). In boys, LH and FSH levels decrease by 6 months of age; However, FSH levels remain high up to 3 to 4 years of age in girls (12, 43, 45). A recent study of full-term and pre-semester babies suggests that nazma feedback brokered by sex steroids, as well as inhibin B, can affect sexual dimorphism for FSH and LH levels during minipuberty (46). In boys, T levels start to rise after 1 week after birth, peaking between 1 and 3 months, and then drop to low pre-age levels by ~6 months (12, 43, 45). These changes reflect GnRH-induced LH activation. During mini-adulthood, T-levels correlate with salvation growth (47), and postpartum T levels were also associated with male-type behavior in toddlers (48). In addition, acne, sebaceous gland hypertrophy, and prostate-specific antigen levels in the urinary tract have been observed, consistent with biological activity androgen (44, 49). The secretion of GnRH-induced gonadotrophin stimulates the production of inhibin B (marker of Sertoli cell number and function) (43) and AMH (50) and Leydig INSL3 cell product (51). High levels of hibin B remain beyond 6 months of age despite the decrease in gonadotrophin secretion (43). Testicular volume (TV) increased during mini-adulthood (12, 52, 53). One critical event during this time is the spread of Immature spermatogonia-induced serole cells induced by FSH, Reflecting the high levels of circulation inhibin B. On average, the Sertoli cell population increased from 260 × to 106 at birth to 1500 × 106 by 3 months of age, and this increase represents a critical determinor for future sperm production capacity in adulthood (53, 54). Despite high levels of intragonal T and gonadotrophin surge, sertoli and sperm cells are not differentiation, and sperm does not initiate. During this time, Sertoli cells express low levels of androgen receptors thus remain immature despite increased T during minipuberty (50, 55, 56). In girls, high gonadotrophin levels cause an increase in the development of ovarian follicles (44, 49). Estradiol levels (E2) also start to rise after 1 week of age (44) and are associated with increased follicles (49), and then decrease during the second year of life (44). High circulating E2 levels in girls lead to tangible breast tissue Mini-puberty (44, 57). The postpartum gondtrophin surge also causes the production of hormonal peptides of the inhibin B granulosa cell (43) and AMH (49). In both sexes, T appears to be an important thyme of growth during infancy (58) and affects neuro-behavioral sexual differentiation (48). In particular, minipuberty appears enhanced in preterm babies and in those born small for pregnancy age [tested inRef. (12)]. The biological significance of mini-puberty and its implications for reproductive ability are not fully understood. This period may be critical to future reproductive health, warranting further investigation. The exact mechanism that leads to the disqualification of the HPG axis after infancy remains largely unknown. Observing a similar pattern of gonadotrophin secretion occurs in boys with anarchidism suggests that the delay of hpg axis at the end of minipuberty is independent of insomniacs (59). Mini-puberty: Implications for CHH phenotypes from a diagnostic perspective, minipuberty offers a unique window of opportunity for early diagnosis of CHH (60). Although there are no obvious clinical signs of GnRH deficiency in female infants, micropenis and cryptrchidism raise suspicion of CHH in male infants, as these signs may reflect the lack of activation of the HPG axis during postpartum fetal life. Large retrospective studies on CHH, including KS, have described a frequency of cryptorchidism ranging from 30% to 50% (61, 62), which is higher than the general population [full-term male neonatal cryptorchidism is 1% to 3% worldwide (63) and 9% in Denmark (64)]. This observation is consistent with the role of GnRH induced T secretion during fetal and mini-muscular life in testicular decline. Reports of the frequency of micropenis among patients with CHH is variable, ranging from 20% to 40% in patients with KS, while a frequency of 0.015% is reported in the general population (65-67). A clinical presentation of CHH during adolescence and normal adolescence is characterized by puberty, increased growth speed, changes in body composition, and psychosocial behavior and culminates with the acquisition of reproductive ability initiated by the reawakening of the GnRH pulse generator after a relatively calm period during childhood (68, 69). LH's GnRH induced pulses first occur during the night, but they gradually increase day and night, resulting in growing puberty and completing puberty (70-73). The exact mechanisms that trigger puberty initiation remain unclear. Maureen studies have shown a dynamic overhaul in GnRH neuron morphology occurring in adolescence, with vengeance >500 spikes associated with increasing synaptic inputs contributing to the sharp increase in GnRH neuron activity (74). Increased stimulant input, such as glutamate, or decreased inhibitor Such as butyric amino β-amino, it seems critical for the beginning of byte houses (75). In addition, the nature of the GnRH heart pulse generator is still under discussion (76). In particular, whether GnRH neurons exhibit an internal pulse generator or if a neural network is required secreting GnRH pulsatile remains unclear (77). A recent study demonstrated the key role of kisspeptin neurons located in the arcuate nucleus in driving GnRH pulsatility in mice (78). Previous studies carried out in girls with Turner syndrome and agony boys have clearly shown that reactivation of the remission age of the gonadotrophic axis does not depend on the presence of functional vandons (79-83). The increase in GnRH induced bodiestrophins during adolescence is critical to stimulate the production of gametes and thus infertility. In males, FSH secretion triggers a second wave of the proliferation of immature serole cells and sperm before semi-tubular maturation. This process is associated with an increase inhibin B, a marker of the Sertoli cell number, and a function (84). Gradually, LH stimulates differentiation of Leydig cells and their steroid abilities, leading to concurrent stimulation of Sertoli cells by FSH and the production of intra-gondil T by LH to lead initiation of spermatogenesis and a spike in television, consisting mainly of adolescent germ cells with an increase in the diameter of seminiferous nodes. During this process, AMH levels start to decline mutually compared to T and inhibin B (85). This finding probably reflects changes in androgen receptor expression in juntiary Sertoli cells, as androgen receptors are found in only 2% to 15% of Sertoli cells up to 4 years of age, while its expression can be viewed in >90% of Sertoli cells after the age of 8 years (55). In particular, AMH levels are starting to drop before any notable increase in testicular size (85, 86). Additionally, insl3 testicular secretion increases during adolescence with a strong correlation to LH levels (87, 88). In girls, the early stages of follicle growth are primarily driven by intra-ovarian factors. However, the onset of adulthood is characterized by an increase in gonadotropin levels necessary for the terminal maturation of the follicles, leading to ovulation (89). LH induced GnRH stimulates the production of androgens by theca cells, while increased FSH is required for the recruitment of ovarian follicles and the aromatization of E2 androgens by granulosa cells (90). AMH concentrations show only slight fluctuations during female adolescence (91), while Tom B, similar to boys, increases during adolescence (92). Clinically, adolescence consists of a series of changes that usually appear in a predictable sequence. However, a noticeable variation in the timing of the beginning of the sage also exists among people of a given and ethnicity, ranging from 8 to 13 years in girls (93) and 9 to 14 years in boys (94). The 140 rate also presents a significant inter-individual variation, with a slightly faster rate of progress in boys than girls (95-97). Several studies have identified a significant correlation between the onset of marital age later and the faster rate of forests in girls (98-101). The latter was proposed as a compensatory catch-up mechanism. Long-lasting tracking of 432 white girls in the United States between 9.5 and 15.5 years has confirmed that the first milestone for the discovery of adolescence is breast development (i.e., thelarche, breast tanner phase 2). Thelarche occurs at an average ~10 years of age followed by the appearance of pubic hair (i.e., pubarche) 4 months later (102). Almost humbly to Tharsh, the speed of growth is starting to accelerate. Growth will continue ~ two years and allows the purchase of ~ 18% of the final height (103). Peak altitude speed (PHV) occurs at an average of 11.5 to 12 years of age, ~1 year after thelarche (96). March takes place ~ months later (99). The median time between the onset of puberty and the ~ 2.5 years (99, 104). Development of secondary sexual characteristics (breast tanner phase 4 and/or pubic hair phase 5) ~1.5 years after menarche. In boys, testicular enlargement (volume ≥4 ml) is the first sign of clinical discovery of puberty, occurring at the age of ~11.5 years and ~6 to 12 months prior to penis growth (i.e., genital tanner stage 3) and pubarche (94, 105, 106). The growth sringe then begins with PHV occurring at the age of 13.5. In a 7-year long-term study, spermatarche, defined as the presence of spermatozoa in urine, was detected at a median age of 13.4 years (range, 11.7 to 15.3 years) (107). This suggests that spermatarche is a relatively early sea age event, often before PHV. Another milestone of male adolescence is the first age of violation. A study of 1582 boys from Bulgaria showed an average age of 13.3 ± 1.1 years for first ejaculation (108). Voice breaking in men is also a clear event that usually occurs between tanner shelby G3 and G4 (97, 109). A retrospective longitudinal study of 463 Danish choir boys showed vocal fracturing at an average of 14.0 years (range, 13.9 to 14.6 years) (110). The development of puberty was completed at an average age of 15.5 years or earlier according to the latest European data (94). Common hallmarks of adolescence in both sexes include bone mass acquisition, changes in body composition, and brain development. Bone changes during adolescence are detailed in bone loss and fracture below. Changes in body composition have different patterns in girls and boys. In early adolescence, the increase in body mass index (BMI) is primarily driven by changes in lean body mass, while increases in fat mass are the main contributor in Adolescence (111). Gender differences are evident, with girls showing higher rates of fat mass gain than boys at all stages, with annual increases in BMI mainly due to increases in fat mass after the age of 16 years (112). Hormonal changes during adolescence also affect the brain by promoting its overhaul and completing puberty that begins with life before and at the beginning of childbirth (113). This has clearly been shown in animal models (114) and is supported by a positive correlation between puberty markers (physical or hormonal) and MRI structural changes in gray matter development and white matter in humans, even after removing the confusing effect of age (113). ... 25% of patients with CHH demonstrate partial GnRH deficiency as evidenced by some spontaneous testicular growth... With a little masculinity... Trends in the age of adulthood outbreak and progress are clear that the average age of menarche decreased significantly between the 19th and mid-20th centuries in many countries (115). This secular trend is linked to improved overall health, nutrition and lifestyle. A large Danish study comparing puberty in girls in two different periods (1991 to 1993 and 2006 to 2008) demonstrated earlier breast development in newborn girls, even when adjusting for BMI. However, the central activation of adolescence has not been proven (93). This progress in breast development may be due to exposure to endocrine disrupters or other factors (116). Studies on adolescence in boys have also suggested an advanced age of early puberty, although more research is needed to confirm this trend. There are racial differences in sea age outbreak (117), though that difference is probably dwindling (118). Delayed adolescence is defined as a puberty outbreak that occurs at age 2 or 2.5 SD later than the population average. The traditional clinical myths applied are 14 years for boys (TV <4 ml) and 13 years for girls (lack of breast development) (6). This definition, however, focuses only on early adolescence without considering progression of adolescence as diagnostic criteria. Recently, the use of adolescent nomograms assessing not only the onset of adulthood but also the progression of puberty (in SD per year) led to a more accurate description of normal adolescence and its extremes (adolescent and inhibitor) (119) (Fig. 1). The most common cause of delayed puberty in both sexes is CDGP, which is often regarded as an extreme version of normal puberty timing. In a large series of 232 patients with delayed adolescence studied at a tertiary U.S. referral center, CDGP accounted for 65% of cases in boys and 30% of girls (120) presents with a delay in puberty. Relatively similar estimates (82% for boys and 56% for girls) were reported in a recent European study, which included 244 patients with puberty (121). Although hers Not fully understood, CDGP has a clear genetic basis, as 50% to 75% of patients with CDGP have a positive family history (122). Open on the New Download Slide tab For further progress in two male patients with delayed adolescence. The TV was serringed on a matching

teenage nomogram. (a) Patient 1 was diagnosed with delayed puberty at the age of 14 (TV 3 ml) and completed the development of adulthood at age 18 (TV 16 ml), confirming CDGP diagnosis. (B) Patient 2 was diagnosed at the age of 15 (TV 3 ml) and released at the age of 17 (TV 8 ml), although his progress was still abnormal (below 2 SD) using a nomogram in adulthood. Therefore, the difference between CDGP and partial CHH remains unclear. [Poggartle nomgram obtained courtesy of Dr. van . CDGP is a diagnosis of exclusion. Other causes of delayed adolescence should be actively investigated and ruled out, including hypogondropic hypogondropics (e.g., Clinfelter syndrome or Turner syndrome)], permanent HH (e.g., CHH, tumors, infiltration diseases), and functional hypogonadotropic (FHH; e.g., systemic disease, anorexia nervuse, excessive exercise). In particular, the differential distinction between CDGP and CHH in adolescence is particularly difficult, as discussed in detail in the transient GnRH deficiency: CDGP below. Management options include an expected observation versus short-term sex steroid replacement (6). The latter mainly focuses on induction of secondary sexual characteristics to alleviate psycho-so-second distress due to crop delay and/or short statority. The hallmarks of CHH in adolescent males. In adolescence, male patients with CHH seek medical attention for absent or minimal masculinity, low libido, and unymving expectancy (123). מהחולים עם 75% ב CHH, מוביל, מתרחשת, אף פעם לא ההתבגרות גיל<4 ml)= and= the= absence= of= secondary= sexual= characteristics= (i.e.,= sparse= facial= and= body= hair,= high-pitched= voice).= in= this= group= (absent= puberty),= micropenis= and/or= cryptorchidism= are= commonly= observed.= in= contrast,= 25%= of= patients= with= chh= exhibit= partial= gnrh= deficiency= as= evidenced= by= some= spontaneous= testicular= growth= (tv=>;אכן .רוב החולים אין כל שפיכה בהגדרה של היפוגונדיזם חמור (124 ,61), אשר לאחר מכן מעכב (4 מל) עם גבריות קטנה, טלוויזיה מופחתת באופן חמור T רוב החולים עם .יש פרופורציות סריס עם טווחי זרוע בדרך כלל עולה על גובה על ידי CHH נדרש לייצור נוזלים הזרעית והתנוע ונפח שפיכה אופטימלי ללא פרץ צמיחה; עם זאת (125) המשקף את הסגירה המעוכבת של האפיפיזיה של עצמות ארוכות בהיעדר סטרואידים מין מוגברת מוביל צמיחה ליניארית יציבה .חוסר רמות סטרואידים נזמה ,סמ 5≤ , the final height is rarely affected (126). Some studies report that adult height in men with CHH exceeds men's height and healthy control </4>Other studies show that CHH adolescents, on average, achieve their national height (126, 130). In a study of 41 men with CHH, a positive correlation was found between the delay of puberty before treatment and adult height, so 6 years or more of puberty delay was associated with ~5 cm greater adult height (128). Alternatively, Dickerman et al (129) reported the growth of 50 adolescents with CHH and found no differences in the normal adult height achieved between boys who were referred before or after the age of 16. Boys in both groups exceeded their predicted final height by 4.9 cm (referred before the age of 16), and by 6.3 cm (referred after the age of 16). Typical changes of body composition in boys with CHH include decreased muscle mass and female body habits with a gynaecological pattern of fat distribution. Mild gynecomastia can be seen in untreated patients due to the imbalance of the T/E2 ratio. Bone maturation is impaired, with bone age suspended and lower bone density observed relative to peers. There is no reported data on micro-archchit of bone of males with CHH, and the risk of fracture is difficult to assess given the lack of large multi-center prospective studies on bone health in CHH. Females. The most common complaint is Amanorah primary in nearly 90% of women with CHH (131-134). Less than 10% of women with CHH had menstrual bleeding (131, 133, 135), which in most cases involved one or two of bleeding during adolescence (primary-secondary amenorrhea) before chronic amenorrhea sets (131-134). Chronic oligomerona was reported, although at a considerably lower frequency (136, 137). Several studies have shown that absent breast development was observed in a minority of women with CHH before estrogen replacement therapy (131-133). Only one multi-center retrospective study described absent breast development in most women with CHH (134). However, this study only included women who are sick with CHH without breast development. Pubarche also shows great variance, ranging from absent to near-normal pubic hair (131, 133). Varying degrees of GnRH defciency may affect ovarian androgen production differently (132) (see below). Furthermore, the leading adrenarche increase production of adrenal androgen (i.e., dehydroepiandrosterone, androstenedione) can also contribute to pubarche (132, 138). Linear growth and final height in women with CHH have been assessed in relatively few studies (129, 139). The published addressed figures indicate that the final height of these women is similar to that of the referral population. In Dickerman et al's series (129), the growth of 16 women with CHH was remarkable, while a slight mid-childhood slowdown in the growth rate of girls carrying FGFR1 mutations was recently reported (124, 139). Clinical presentation of CHH in adulthood despite Introducing adolescent CHH is more common, and some patients do not seek medical attention until adulthood. At this point, low libido, infertility, or less common bone loss and fractures are the most common complaints. Although male patients typically exhibit prepubertal or small degrees of spontaneous testicular growth, a larger TV with preserved spermatogenesis has been observed in a group of male patients (called prolific eunuch syndrome). These patients exhibit low serum levels of T in the definition of undetectable gonadotrophins. The presence of low amplitude and/or low frequency or sleep entrained GnRH pulses is considered sufficient to support intra-intestinal T production, but not able to achieve normal T-cycle levels for full virilization (140). Very rarely, CHH is diagnosed in older age. Recently, Patderska et al. (141) described six cases of men diagnosed with CHH after 50 years of age and there was a not long-term standard hypogundism. These patients exhibited adverse health events such as osteoporosis (six out of six), hypercholesterolemia (four out of six), and anemia (two out of six). Body composition and cardiovascular events have not been recorded. To the best of our knowledge, there is no report of unsanced women until menopause. Furthermore, data on the natural history of CHH in older men and women is missing. In addition, a small subset of patients are present with hypogonadotropy in old age (AHH). These patients report normal development of the homes and then a complete delay of the HPG axis leading to severe HH. No central nervous system abnormalities or risk factors for functional deficiencies in GnRH (142) have been cleared, and follow-up studies on AHH have shown a lack of recovery (143). The psychological impact of CHH is often neglected. The absence of sex hormones and its effect on physical appearance are major sources of psychological distress for hypogonodyllic males (144). Specifically, CHH can be accompanied by anxiety and depression (124, 145), and these symptoms are often underestimated by doctors (146). Low self-esteem and different body image have also been reported (147) and can prevent adequate psychosexual development (124, 148). Similarly, psychic distress was observed in female patients with CHH. A recent online survey indicates an adverse perception of women with CHH on their health conditions, with a predisposition to depression (149). The same study suggests that care providers often do not adequately address these issues, and according to patients there is even a tendency to reverse the psychological consequences of their poor birth development (149). It is also quite possible that the misconceivedness of their potential infertility (see below) is also a major contributor to their distress. Reversal of CHH although CHH was previously considered as Condition, it is now known that a subset of patients with CHH spontaneously restore the function of their reproductive axis after treatment (150-153). Reversal occurs in both male and female patients with CHH, and it seems more common (~10% to 20% in men, and some case reports for women) than previously thought (150-152). Patients with reversals extend to the range of moderate to severe GnRH deficiency, and many port mutations in the basic CHH genes. However, so far there are no obvious clinical factors for reversible CHH prediction. Similarly, the genetic signature for reversal remains unclear, though enrichment of TAC3/TACR3 mutations has been observed in one series of patients (151, 154). Importantly, recovery of reproductive axis function may not be permanent, as some patients experience withdrawal to a state of GnRH deficiency (151, 153), so long-term monitoring of reproductive function is needed. Thus, patients with reversal experienced CHH (i) represent the moderate end of the clinical spectrum, (ii) demonstrate the plasticity of the GnRH neural system, and (iii) emphasize the importance of the effects of environmental (or epigenetic) factors such as sex steroid therapy on the reproductive axis. Indeed, sex steroid treatment was the only common denominator in patients experiencing reversal. Normalization of the sex steroid miliem may trigger maturation of the GnRH neural network at least in a subset of patients, as the expression of critical genes for GnRH ontogeny are sex-responsive steroids (155, 156). CHH-related CHH-related phenotypes can be associated with non-productive phenotypes. Anousmia (i.e., lack of sense of smell) was observed in ~50% of CHH cases (157, 158), and this occurs in KS. The interconnected relationship between GnRH systems and olfactory systems in early developmental stages explains this relationship (see HPG axis embryonic development above) (159). Other phenotypes are also associated with CHH, although at a lower incidence. They include mirror movements (sinkinesia), unilateral kidney agenesis, eye movement disorders, sensorineural hearing loss, midline brain defects (including absence of callosum corpus), cleft/thyme lip, dental agenesis, snail defects, and cardiovascular defects (7, 157, 158, 160) [figg. Three large studies have assessed the prevalence of these associated phenotypes in CHH, although these studies have been retrospective without systematic evaluation for CHH-related phenotypes (157, 158, 160). Are in Table 1 (157, 158, 160, 165-170). OMIM (finds 46 complex syndromes that include this feature. In this review, we compiled a table of syndromes that have clinical and genetic overlap with CHH [Table 2 (162-164, 171-191]. (a) A coronel CT scan showing the normal platinum object in a normal subject (yellow circle). (b) Cleft palate (yellow arrow) in a patient with a hetero-present FGFR1 mutation. (c) Iris depigmentation of the left eye in a patient with an SOX10 mutation. (D) Oculomotor nerve paralysis suggests left-left cranial nerve damage in a teenager with KS and heterosigm CHD7 mutation. (E) An abnormality in the ear meddle indicates CHARGE syndrome in a male patient with CHH was initially referred for KS. (f) An inner ear CT scan shows hypoplastic semi-circular trenches in a male patient with KS and deafness resulting from the hetero-terrogygenic SOX10 mutation (g) and postpartum kidney ultrasound; A left rear fossa look shows a left kidney-free male neon with an ANOS1 mutation. Spleen. (h) Right kidney ultrasound in the same patient reveals compensatory hypertrophy (dotted line indicates kidney length of 65 mm). [A and B) Adapted with the approval of Maione L, Benadjaoud S, Eloit C, et al. Computed tomography of the anterior skull base in Kalman syndrome reveals specific abnormalities in the ethomoid bone associated with olfactory bulb defects. J Clean Endocrinol From Tab 2013; 98:E537-E546. Illustration of copyright presentation by the Endocrine Society. (C and f) restored with permission from Maione L, Brailly-Tabard S, Nevoux J, et al. Letter to the editor: Hypogonadotrophic reversal congenital hypogonadotrophic in a person with Kalman syndrome due to the SOX10 mutation. Clean Endocrinol (Oxf) 2016; 85:988-989. (g and h) copied with permission sarfati J, Bouvattier C, Berry-Gauillard H, et al. Kalman syndrome with FGFR1 and KAL1 mutations detected during fetal life. Orphans J Rare Diss 2015; 10:71.] Table 1.Prevalence of primary un productive phenotypes in CHH versus general population phenotypes. All CHH. Ks. (n = 106) (Waldstreicher et al. . 158) ' קווינטון ואח) (n = 215) . 158) ' קווינטון ואח) (n = 112) . 160) ' קוסטה ברבוסה ואח) (n = 219) . תנועת מראה 0.01% 100% 100% 52% 55% אנוסמיה/היפוסמיה . אוכלוסייה כללית NA 20% 31% 19% 0.0001% Agenesis כליות חד צדדית NA 10% 15% 8% 0.05% 27% 20% 3% הפרעות תנועת עיניים NA 0.02%–0.0002% 5% 6% ליקוי שמיעה 8%a 15% 0.02% 7% חך / שפה שסועה 5%שיניים (165) 0.1% 6% 4% agenesis NA 14% 4%-7% (166) Syndactyly, polydactyly, polydactyly, camptodactyly NA NA 5% 0.03%–0.1% (167) 0.2%-1.3% (168) 1% (169) עקמת NA NA 13% 0.05%–0.1% (170) תסמונות מורכבות עם תסמונת קלינית וגנטית עם תסמונת 2.טבלה CHH . סימנים קלים . סימנים עיקריים Overlap with CHHa. CHARGE Coloboma syndrome, choanal atrasia, semicirtic hypothalamus-pita brain dysplasia, sensorineural hearing loss, ear defect, mental retardation, congenital heart defect CHD7 (162, 171-174); SEMA3E (175, 176) Vardenburg Syndrome Sensorineral Sensorineral Impairment, Abnormal pigmentation HH, anosmia with olfactory/hypoplasia of the olfactory bulb, facial dysmorphism, megacolon, semicir detached canal dysplasia, congenital heart defect SOX10 (163, 164, 177, 178) Hartsfield syndrome splitting hand/foot defect, holophropenpelli anosmia, Hypothalamic-pituitary defect, syndactyly, face dysmorphism FGFR1 (179-182) hypoplasia adrenal glands congenita HH, adrenal hypoplasia — NR0B1 (DAX1) (183, 184) 4H HH syndrome, hypodonia, hypomyal Sleep — POLR 3B (185, 186) Septo-optical nerve hypoplasia, hypothalamus-cerebral hypoplasia, middle brain defect - HESX1 (187, 188) SOX2 (189-191) Epidemiology no rigorous epidemiological study on the prevalence of CHH. Two historical studies that examined military records provided some estimate of the prevalence of this disease. One study examined 600,000 sardine recruits during their military testing and identified 7 cases with regular cryotype showing bilateral testicular atrogent anousemia (considered as KS cases), and therefore estimated that the incidence of KS is 1 in 86,000 in this population (192). A second study identified 4 cases of HH among 45,000 French men in the military service display, thus edging out that the incidence of CHH is 1 in 10,000 (193). There is no study on the prevalence of females with CHH. In a series from Massachusetts General Hospital of 250 consecutive CHH cases, the ratio of male to female is 3.9:1. However, this ratio decreases to 2.3:1 when the family cases are analyzed separately (140). A recent epidemiological study examined the release logs of all five university hospitals in Finland estimated that the incidence of KS is 1 in 48,000 in the Finnish population, with a clear difference between males (1 in 30,000) and females (1 in 125,000) (65). Bias regarding the reduced incidence of CHH in females the prevalence of CHH is historically considered biased toward male domination (male-to-female ratio of 5:1) (157, 158). The latest work suggests that the sex ratio is closer to 2:1 (133, 134). Furthermore, sex ratio analysis for CHH in families with autosomal inheritance demonstrates that the sex ratio is close to being equal (194, 195). Importantly, partial CHH may still be properly diagnosed due to a delicate clinical presentation that resembles functional hypothalamus amenurea (131, 196). A number of possible explanations for the lower diagnosis of CHH in females follow:Over the past decade, there has been a refinement of the spectrum of GnRH deficiency in CHH in both males and As the hallmarks of CHH have been for a long time without puberty, leading to an overestimation of the prevalence of CHH in the past (131, 133). In the 1990s, it was thought that CHH-linked X was common so women with CHH were rare. This dogmatic view was gradually challenged by the first descriptions of women sick with CHH harboring bial GNRHR mutations, with varying degrees of breast development (135, 137, 197, 198). Later, a variable level of people's age development was described for females with CHH carrying mutations in autosumal genes (for example, FGFR1, PROK2/PROKR2 or SOX10) (65, 136, 164, 180, 199-201). Finally, in some countries, patients with mild, inexoric forms of CHH are more likely to be treated with contraception or hormone replacement therapy (HRT) by their general practitioner or gynecologist instead of getting a full test and accurate diagnosis. Diagnosis of CHH Minipuberty Minipuberty Clinical Diagnostics provides a short window of opportunity to diagnose CHH. For male babies, microfins with or without cryptorchidism can be a hint of CHH. In such cases, hormone tests at 4 to 12 weeks of life may be used to aid diagnosis (60, 136, 202-207). Typically, low levels of Serum T, LH, and FSH are reported [Table 3 (136, 202-207)] based on comparisons with established reference ranges (43, 208). However, hormonal tests are not a routine prescription for male babies with micropen or cryptorchidism. A recent study reported hormonal data and normative reproduction from a large group of healthy babies (209), which would make it easier to interpret hormonal outcomes. Newborns born from one parent with CHH should undergo a hormonal evaluation during mini-adulthood. The lack of typical clinical traits in female infants suggests CHH explains why the diagnosis of CHH in newborns is rarely made in this species (7, 139, 205). Table 3.Clinical and Biochemical Characteristics of Neonatal Males with CHH Reporting in The No Literature Case. Clinical signs. Hormonal tests. Diagnostic. Neonatal care. References. Neonatal signs. Family history. Gil (Moe). Tee (withering/l). LH (IU/L) . FSH (IU/L) . 1 micropenny hyposmia 4 n.d. n.d. 0.18 CHH hCG, T (202) 2 testicles costs CPHD 3.5 n.d. 0.07 0.18 CPHD T 3 micropenny without 0-7.9 n.d. 0.05–0.17 CHH rFSH + rLH, T (203) 4 Micropenny n.r. 2 0.03 0.19 0.19 CPHD rFSH + rLH (204) 5 Micropenny n.r. 3.5 0.06 0.03 0.12 CHH rFSH + rLH 6 Micropenny, cryptorchidism, CLP, SHFM CHH, CLP 2 n.d. n.d. 0.4 CHH rFSH + rLH (207) 7 Micropenny KS 1 0.1 0.04 0.18 KS rFSH + rLH (136) 8 Microfan Yes, cryptorchidism though 3 0.3 n.d. n.d. CHH T (205) 9 micropenny, cryptorchidism n.r. 6 0.2 0 0.4 CPHD rFSH + rLH (206) 10 micropenny, + rLH 11 micropenny, cryptorchidism n.r. 2.5 0.1 0.1 0.8 CHH rFSH + rLH 12 Cryptorchidism n.r. 5 0.1 n.d. 0.3 CHH rFSH + rLH 13 micropenny, cryptorchidism n.r. 0.25 0.2 n.d. 0.21 CHH rFSH + rLH childhood during childhood, diagnosis of CHH is very challenging, as childhood is a hypogondal and physiological period, consistent with the relative attastion of the GnRH pulse generator. Patients can demonstrate missing persons (TV <4 ml) or partial puberty (119). Typically, the hormonal profile shows hypogonadal T or E2 levels and low/normal serum levels of gonadotrophins due to GnRH deficiency. However, CHH remains a diagnosis of exclusion (see CHH differential diagnosis below). Between 14 and 16 years of age, CHH is difficult to distinguish from CDGP, a common cause of delayed adolescence (see Transient GnRH deficiency: CDGP below). Evaluation of CHH-related phenotypes is important to assess the presence of CHH-related phenotypes that may indicate a diagnosis of CHH and have a specific tool for genetic counseling:A history of cryptorchidism with or without micropenisDecreased or numb of odor, suggests KS, exists in about half of the CHH population and should be evaluated through a revised smell test (158). An official smell test is particularly critical, as 50% of CHH who have reported a normal sense of smell are actually hyposmic or anesmic by revised tests (210); In very young children or in the absence of available olfactometry, MRI imaging may be useful as a surrogate for smell testing when it shows hypoplasia of a scent bulb or aplasia (see below)Congenital sensorineural hearing loss should be systematically evaluated with an audiogram, As hearing loss is generally mild or one-sided, therefore patients may be aware of their deficit in bisexual sinkinesia (mirror movements)dental agenesis best evaluated by panoramic dental lipsCleft and/or thyroid, as well as other defects in the middle line Agenesis unilateral kidney or deformity of the urinary tract, both of which should be assessed by ultrasound kidney and crystal deviations such as scoliosis, Polydacty, and clinodactyly other stigamate pigmentation defects of CHH syndrome forms, e.g., heart defect, ear anomalies outward, and columoma for CHARGE syndrome (see table 2) Biochemical tests in gonadotrophins Most men and women with CHH have very low circulating gonadotrophin levels (61 123 , 132), and most patients with absent puberty demonstrate apulsatile patterns of LH secretion (61). Patients with partial puberty can have low normal circulating gonadotrophin levels, which is inappropriate in the definition of low sex hormones (T or E2) (131, 132) (trait 3). Open on new tab Download SlideHormone Cheats and Ultrasound Features in Female Patients CHH vs. Health Controls. (a) Serum FSH and LH, (b) E2, (c) inhibin B ovarian peptide serum, and (d) AMH levels in untreated women with CHH (n=68, aged 18 to 34 y) and age-compatible healthy young women (controls, n= 52). (e) Mean autofocus number (f) in total ovary in untreated women with CHH (n= 39) and in healthy women (n = 41). **P < 0.01; P < 0.0001. [Adapted with approval from Berry-Gauillard H, Larrat-Ledoux F, Levaillant J-M, et al. anti-molecular hormone and ovarian morphology in women with isolated hypogonadotrophic hypogondropic hypogonism/Kalman syndrome: effects of recombinant human FSH. J Clean Endocrinol From Tab 2017; 102(4):1102-1111.] Ethardiol females. Circulating E2 levels in women with CHH are usually low or at the lower end of the normal range during the follicle phase when using sensitive data with an identification threshold of 10 pg/mL (132, 211) (image. 3). In contrast, the more common vaccines have poor sensitivity and are therefore inaccurate in this clinical environment (131, 134). Sea sensitive E2 may even cause misdiagnosis or confusion with other causes of ovulation (211). Males. Although Serum E2 levels are not necessary for clinical diagnosis of CHH, they are consistently lower in men with CHH compared to normal males using sensitivity tests (138, 212) and can have an impact on bone health and metabolism (213-215). Remember testosterone. Circulating T levels in patients with CHH are generally low, all <3 nmol/L (86.5 ng/dL). This is usually also the case for patients with CHH with partial puberty and larger TVs (61). Females. Low circulating androgen levels (androstendione and T) are reported in women with CHH despite normal circulating concentrations of dehydrophyndrosterone sulfate (132). This relative androgen deficiency is probably due to poor stimulation of theca cells by low-circulating LH. Indeed, T serum levels increase in women with CHH during combined recombinant LH (rLH) plus recombinant FSH stimulation (rFSH), while T levels do not change with rFSH alone (132). The GnRH test for the cerebral gonadotrophin response challenge test GnRH was specially evaluated in men and women with CHH (137). Males. In men with CHH, the LH response varies greatly and is suitable with the severity of gonadotrophin deficiency. However, the latter has been clinically reflected by the degree of testicular degeneration, which questions the added value of the GnRH stimulation test (135, 201, 216, 217). Females. The response of the aphid gonadotrophy to the GnRH test was assessed in only a few case reports (137, 139). In most women with GnRH deficiency, the peak LH response to GnRH stimulation was relatively blunt for normal women (137). The males of no life in me. Inhibin B is a differentiation hormone by Sertoli cells and reflects sertoli cell number and function (218, 219). Inhibin B is under out of FSH (220, 221). Healthy post-pubescent saminifer tubes also regulate Inhibin B production, most likely through control of spermatids (222). Most men with CHH with puberty absent with/without microphine cryptorchidism demonstrate low levels of serum B serum (<30-60 pg/mL), indicating a reduced population of Sertoli cells (66, 123, 223). This is consistent with the lack of FSH-induced GnRH stimulation of cminnifer ducts during fetal life and mini-publicization (45, 66, 217, 224). Higher levels of good faith in serum B are encountered in a minority of patients with absent adolescence, but are found in most patients with partial puberty (61) or acquired HH (225), consistent with strong activation of the HPG axis during minipuberty. Serum B levels are well correlated with testicular size (61), and low inhibin B level is a negative predictor of infertility (66). Furthermore, some studies have shown a good discriminatory value of inhibin B serum to differentiate chh severe CDGP (see below) (121). Females. Inihibin B is a marker of the number of port follicles and is secreted by granulosa cells (226). Very few studies have investigated circulating inhibin B levels in females with CHH (132). Low B concentrations are reported in the range of pre-age girls (227-229). One study demonstrated the critical role of FSH to stimulate ovarian inhibin B secretion as evidenced by increased inhibin B levels in response to rFSH alone, but there is no further change in response to both rFSH and rLH (132). Males are an anti-Mullerian hormone. Circulating AMH levels in male patients with CHH were studied during the preterm period and in adulthood (before and after gonadotrophin or T treatment) (204, 223, 230). During minipuberty, CHH babies have low AMH levels, which can be normalized by rFSH and rLH therapy (34, 204). Adults not treated with CHH have high AMH levels compared to normal men, but in the low to normal range of pre-adulthood levels in normal boys, indicating the immaturity of the Sertoli cell population (223). rFSH treating previously untreated patients with CHH causes the spread of jugeneral cancer cells, thus increasing AMH levels, while the following hCG treatment will increase intra-intestinal T levels and dramatically reduce AMH levels (223). Females. Average serum AMH concentrations are significantly lower in women with CHH than in healthy women (image 3) (132), although two-thirds of patients display serum AMH levels in the normal range. The sub-group of women with CHH with the lowest ovarian volume (OV) and antr follicle count was significantly lower and AMH levels consistent with lower FSH levels. However, low AMH levels should not be considered a poor fertility prognosis, as both pulsatile GnRH and gonadotrophin management can lead to infertility and will be accompanied with an increase in Serum AMH levels. Pituitary hormones in chh's evaluation, it is important to rule out other pituitary gland defects by conducting an investigation of the full pituitary axis (e.g., to rule out hyperperolectin) (231) (see CHH genetics below). A basic profile including measurements of prolactin, free T4, TSH, morning cortisol, and IGF1 should be made and the growth curve should be analyzed. In case of suspected failure to need the pituitary gland, appropriate dynamic challenge tests and dyancephal imaging (231) must be performed. Radiological examination and pelvic ultrasound studies on uterine morphology in women with limited CHH (131, 132, 232). Pelvic or transvaginal ultrasound (when necessary) demonstrated a significant reduction in mean OV compared to healthy older women of a similar age (131-133, 232). OV corresponds to the severity of deficiency E2 (232) and body lining equilibrium (233). In particular, the OV decline is greater in KS than in normous CHH with a trend towards lower serum gonadotrophin levels in KS, suggesting a more severe GnRH deficiency (131). The only study that turned up the number of ovarian port follicles (AFs) showed a significant reduction in the average number of AFs compared to normal, age-matching women, consistent with the lower levels of AMH (132). Therefore, a combined reduction in OV and AF count is a phenotypic characteristic of women with CHH, mistakenly considered a poor fertility prognosis. However, OV and AFs respond positively to gonadotrophin stimulation in females with CHH (see below). Testicular ultrasound the measurement of testicular size is important to determine the severity of GnRH deficiency and track the progression of testicular maturation during fertility treatment. Although an orchid is often used in clinical practice, testicular ultrasound has the advantage of assessing not only size but also localized testicles. Both methods were equally accurate in the hands of an experienced physician (234, 235). As expected, the gauge orchid too much tv value by ~6 ml compared to ultrasound, most likely due to the disturbance of the surrounding soft tissues, and has low sensitivity in detecting testicular atymmetry (185). Therefore, ultrasound has the added benefit during a basic assessment to simultaneously estimate the size of the testicles in detail and to stopped kidney defects during a single assessment. However, subsequent assessments can be performed reliably with an orchid. An MRI in the brain is performed at the base to exclude hypothalamic-pithoid lesions and assess defects in olfactory bulbs, klossum corpus, semicircle trenches, cere auditory (207, 236), and midline (237). Patients with KS typically exhibit unilateral or bilateral bulb agenesis, olfactory system agenesis, and/or deformity associated with their anesmia/hyposmia (238). However, some patients with KS have Olfactory structures despite clinically approved anesmia. In this minority of patients, it seems useful to look for other causes of congenital or acquired anesmia (e.g., viral infections, trauma). Furthermore, an anomaly of semicircal canals is an important finding, as it suggests the diagnosis of CHARGE syndrome (239). Bone density and CHH test microarchit should include measuring bone mass by using double-energy X-ray absorption (DXA) to assess bone mineral density (BMD) (7). Bone quality can be assessed by processing a trabecular bone score or by performing a high-resolution peripheral peripheral CT. The latter provides a more detailed assessment of bone micro-archichit at peripheral sites (e.g., distel radius, throb) (240). Alternatively, a trabecular object score is a textual index that evaluates pixel gray-level variations in the luminosity spinal DXA image, providing an indirect index of trabecular micro-architecture, easily available from DXA Scanning (241). Bone testing should be done at the base and repeated at least 2 years after HRT to assess the beneficial effect of sex steroids on bone mass and subsequent monitoring guide. The use of FRAX, a clinical algorithm for assessing fracture risk, has not been verified in this particular population (242). Other olfaction function tests represent a hallmark in the clinical evaluation of CHH, as ~50% of patients have a olfactory defect (KS, also known as dysplasia-olfacto-genitals) (243). The olfactory function is evaluated using semi-quantum methods such as the UPSIT score (210) or the Sniffin' Sticks tests (244, 245), which give age and sex-compliant scores relative to the referral population. Alternatively, volatility-stimulating potentials (246) can be used, although they are less practical in a clinical environment. Partial or subtle odor impairment can be seen in certain patients (i.e., hyposmia or microsmia), raising the question of sequencing rather than binary classification (210, 247). While self-reporting anosmia is sensitive and specific, self-reporting of a normal sense of smell is unreliable (210). Therefore, official odor tests should be continued for all patients with CHH. Hearing incidence of hearing loss in CHH is reported to be between 5% and 15% (table 1). Neverth caption, there are no large studies with systematic assessments of hearing in patients with CHH, as audiogram is rarely performed during basic evaluation. Hearing loss ranges from unilateral and moderate hearing loss to bilateral sensory deafness; However, you rarely experience conductive hearing loss (158). In particular, chh's association with hearing loss indicates mutations in specific genes (e.g., CHD7, SOX10, IL17RD) (7, 160). Spermiogram spermicgram is defined as a major and divine analysis of To assess male fertility potential (248). Among the main parameters, ejaculation volume (which is T dependent) as well as sperm motility and morphology are the most critical. The world health organization's (WHO) latest criteria for interpretation of sperm analysis were published in 2010 (249) based on semen samples from >4500 men in 14 countries and set the lower reference limits for the following parameters: 1.5 ml for sperm inflate, 15 million ml per sperm count, 40% for total moderation, and 4% for normal morphology. Most patients with CHH at the base (especially those with severe hypogonodism) exhibit severe impotence and lack of ejaculation, making spermiogram impossible. However, with fertility treatment most males with CHH will develop sperm in their palette. Interestingly, the concentration of sperm needed for fertilization in patients with CHH is much lower compared to health organization guidelines (250). In conclusion, spermiogram is marked at the base (when possible) and serially after initiation of fertility treatment. Genetics of CHH genetic determinants of puberty timing The timing of adolescence varies widely in the general population and is influenced by genetic, environmental, epigenetic factors (3). The studies of higgin timing in families and twins provide evidence that 50% to 80% of this variability is caused by genetic factors (3-5). Recent genomic association (GWASs) studies in large populations shed light on the underlying genetic determinants of the untiebility of house timing. By studying ~370,000 women of European ancestry, day et al. (251) Reported ~400 independent loci strongly associated with age in menarche. The individual effect size of each locus ranges from one week to one year; However, the cumulative effect of all detected genetic signals only accounts for 7.4% of the age population's emanation in its monarchies. Similar results appear to be GWASs on the timing of puberty in men using age in voice break as a proxy for the timing of puberty. A large number of loci is identified as involving BMI, height, and epigenetic regulation consistent with the critical connections between energy balance, growth and development, and reproduction. Furthermore, a subset of loci involved in the timing of adolescence are located in embedded areas (e.g., MKRN3 and DLK1), which exhibit important effects when inherited pity (251). In particular, some loci menarche are enriched or near genes that underpin CHH (e.g. FGF8, GNRH1, KAL1, KISS1, NR0B1, TACR3) or centrally traced adolescence (MKRN3). In summary, forest timing is a highly polygenic trait, likely involving many individual genetic loci. Further studies of larger cohorts with well-studied phenotypes are needed to expose genetic actors and determine the contribution of genetic-environmental interactions. Positive family history of CDGP cannot control CHH Genetics A number of recent reviews have focused solely on chh genetics, including a review by Stamou et al(252) in this journal (194). Over the past year, four other genes have been reported to the basic CHH: KLB (253), SMCHD1 (254), DCC, and its NTN1 ligand (255). Hereby, we summarize the complexity of CHH genetics. Since the first description of the genetic aspects of primary eunuchs by Der Franz Kalman, in 1944 (256), the genetic complexity of the disease has been discovered. Reflecting CHH's clinical heterogeneity, genetic heterogeneity also prevails, with mutations >30 genes identified so far. These genes were critical in exposing the complex sophistication of GnRH neurons: (i) defects in the GnRH fate specification; (2) defects in the guidance of the neuron GnRH/guidance for the olfactory axon; (iii) abnormal neuroendocrine secretion and homeostasis; and (4) defects in gondotrope (Tamada 4) (7, 140, 194, 252, 257). However, >50% of cases remain without a genetically identified cause. Open on the New Download SlideGenetics tab in CHH. (a) The timeline of gene discovery in overlapping CHH and CHH documents. (B) Biological involvement of CHH genes in the GnRH neural system. Inslet penetrating and variable expression were also observed [Fig 5 (258)]. In addition to the Mandelian states of succession, uligoganism was also reported in the CHH. In 2007, loss-of-function mutations in two CHH genes that work in concert were described in two probands (259). The systematic screening of eight CHH genes in 2010 in a large group of CHH detected olygoganism in 2.5% of probands (260). Later studies screening more and more CHH genes demonstrated even greater degrees of olygoganism, ranging from 7% (261) to 15% (262). The advent of high throughput sequencing dramatically improves the ability to detect multiple rare variants in a patient. However, the appreciation of the pathogenicity of one version and the synergetic effects between variants remains challenging. Open on the new download slidepedigrees and gene mutations in patients with CHH and patients with KS. All listed gene variables are rare (allel frequency <0.5%) And is expected to be damaged by standard protein prediction algorithms (SIFT and/or PolyPhen2). All versions are classified as pathogenic or reasonably pathogenic according to the recommendations of the American College of Medical Genetics (258). Genealogy 1: KS-linked X is caused by the ANOS1 mutation. Genealogy 2: Automatic recessive state of inheritance. Genealogy 3: De Novo mutation. Genealogy 4: A dominant autosumal with reduced penetrating. Genealogy 5: An uligogical mutation with de novo mutation in FGF8. Circles indicate females, squares indicating males and arrows indicating A diagonal slash through an icon means the subject is dead. Regarding gene mutations, + represents a sequence of wild type (reference), and 0 exists in male subjects who merge into genes in the X chromosome. Indeed, phenotypic wealth found in CHH syndrome is not always associated with contingency gene syndrome (e.g., major deletion in Xp22.31 in a patient with KS, punctual chondrodysplasia, and ichthyosis, including ANOS1, ARSE, and STS) (263). Instead, it may result from mutations in pleiotropic genes that can affect unrelated phenotypic properties. For example, dominant FGFR1 mutations can cause CHH with or without anozmia (180, 181), Piper syndrome (264), Holofersenspal (265), Hartsfield Syndrome (179) or CHH with a split hand/leg destrestment (207). These varied phenotypes may arise from various mechanisms such as the type of mutations (loss or gain of function, flu-yinsapines, dominant negative) or, alternatively, be influenced by sub-shields, which are consistent with an olygoganic model of inheritance. Furthermore, different constellations of CHH-related phenotypes define CHH syndromes with clinical and genetic overlap [e.g., SOX10 mutations causing Waardenburg syndrome (177, 266) or KS (CHH with anosmia) (164)] (Table 2). Distilling these CHH-related phenotypes greatly improves the diagnostic yield of targeted gene screening. Indeed, while FGFR1 mutations occur in ~10% of patients with CHH, they are present in 87% of patients with both CHH and a split hand/leg mample (207). Similarly, while SOX10 mutations underlie 4% of KS, SOX10 mutations are found in 30% of patients with KS and hearing loss (7). This genetic advance challenges the traditional phenotyphal classification of syndromes. Differential diagnosis of structural CHH causes structural factors that affect the hypothalamus-cerebral axis and may lead to acquired HH. These factors can be classified as tumors (adrenoma in the adrena, craniopharyngeomas, and other central nervous system tumors), screening, surgery, apoplexy, or permeable diseases (i.e., chromatososis, sarcoidosis, histocytosis). Less commonly, head injury or subarachnoid hemorrhing could be linked to acquired HH (267-269). Most patients with structural reasons have multiple parasym hormone deficiencies in addition to acquired HH (268). In early adolescence, an MRI in the brain is marked in patients with delayed adolescence and HH when there is a break from growth spurt, lack of the parabolic hormone (including bland diabetes), hyperprotectine, and when there are symptoms of mass effect (headache, visual impairment, or visual field defects). In adolescence or late adulthood, brain MRI is marked in patients with isolated severe HH <5 nmol/L, high suspicion of CHH) and patients with combined adebral hormone deficiency (CPHD), hyperpolectin, or innuendo symptoms of sellar mass (267, 268, 270). Genetic causes: CPHD CPHD is a rare congenital disorder characterized by poor production of the aphid hormones that affect at least two frontal adotage hormone precipitation with varying clinical manifestations. CPHD may manifest as (i) insulated pituitary hormone deficiencies, (ii) a component of other syndromes (i.e., septo-optical dysplasia, which combines CPHD with optic nerve hypoplasia or midline defects), or (iii) pituitary gland disorder syndrome with the intrauterine pituitary gland (271). To differentiate CPHD from CHH, a biochemical evaluation of adural function with measurements of IGF1, morning cortisol, TSH, and T4 free prolactin is required in addition to evaluating specific clinical expressions of selective anterior aduital hormone deficiency. Even subtle signs of dissedation for one of the adebral hormones warrant further testing with dynamic challenge tests suitable for brain MRI (231). Transient GnRH deficiency: CDGP During early adolescence, distinguishing CHH from CDGP is very challenging, as adolescent delay is a hallmark of both diseases, and HH exists in both. While GnRH deficiency is permanent in most cases of CHH, CDGP is a condition of transient GnRH deficiency where puberty eventually begins and is completed without hormone therapy (6). Additionally, CDGP is a common cause of delayed adolescence, while CHH is much rarer. The CHH distinction from CDGP is critical to allow early diagnosis of CHH, avoid delay regarding hormonal replacement, and ease the psychological burden associated with delayed puberty (7). In addition, from a prognostic point of view, to differentiate a transient condition from a chronic disease will affect the patient's quality of life (7). We look at some features that may help in this differential diagnosis, and note that although individual indicators may not provide a definitive solution, a combination of multiple indicators and clinical observation will strengthen arguments for or against a particular diagnosis (Image 6): Open on the new SlideDownload SlidePractical algorithm of clinical management for patients with delayed adolescence. An asterisk (i.e., ▼TV*) indicates an increase of TV under T treatment or after a highly therapeutic window indicating CDGP. INB, speed B.Growth inhibin was recently proposed to help differentiate the various etiology of delayed adolescence (6), but this was subsequently shown to offer no further diagnostic value in the separation between CDGP and CHH (121, 126). Testicular size may discriminate against boys with CHH from those with CDGP. In a retrospective study of 174 boys with adolescence suspended at 14 to 15 years of age, TV's at 1.1 ml (clinically measured) showed 100% sensitivity and 91% specificity to distinguish CHH from CDGP (121). The presence of cryptorchidism and/or micropenis strongly claims in favor of CHH, reflecting the absence of gonadotrophins and sexual hormones during fetal life and mini-puberty (6, 121). In a series of 174 boys referred to a tertiary center for evaluation of delayed adolescence, cryptorchidism was present in 36% of boys with CHH and only in 2% of boys with CDGP (126). CHH-related phenotypes argue against diagnosis of CDGP. Primarily, congenital anosmia (i.e., not related to facial trauma, surgery, or chemical exposure) favors a diagnosis of KS. The presence of anosmia or other CHH-related phenotypes may favor a diagnosis of CHH, but should also be weighed against their frequency in the general population (Table 1). A positive family history of CDGP cannot rule out CHH, as CHH families are often enriched for family members with CDGP (157). In addition, the autosomal dominant inheritance appears to be both CHH and CDGP (122). Biochemical Assessment: To date, no biochemical marker can fully differentiate CHH CDGP (272) from early adolescence. A GnRH test may be useful for identifying serious cases of CHH. Indeed, when the irritated LH response to GnRH is blunt, CHH is highly likely. A recent study included 19 patients with CHH and 181 patients with CDGP and demonstrated detached LH's irritated GnRH of 4.3 IU/L to identify CHH with a sensitivity of 100% and ships of 75% (121). Inhibin B levels are also a useful diagnostic appendix, with <60 pmol/ml)= suggesting= severe= gnrh= deficiency= (121).= nevertheless,= some= overlap= existing= especially= between= partial= chh,= cdgp,= and= healthy= controls= (273,= 274),= thereby= highlighting= the= need= larger= = prospective= studies.= higher= amh= is= suggestive= for= chh,= although= cut-off = is= not= clear= (274,= 275).= furthermore,= other= markers= such= as= insl3,= dehydroepiandrosterone= sulfate,= and= igf-1= do= not= improve= accuracy= for= differential= diagnosis.genetic= testing= is= a= promising= prospect;= however,= evidence= to = whether = chh = and = cdgp = exhibit = common = or = distinct = genetic = backgrounds = unclear.= mutations = in = igsf10 = have= been = reported = both= cdgp= and= chh= families= (276).= a= shared = genetic = basis = also = partly = supported = by = previous = work = identifying = putative = pathogenic = mutations = mutations = known = chh = genes = in = 14%= of= cdgp = probands= (277) ,= which= was= higher= higher= in= controls.= furthermore,= meta-analysis= of= gwass= including= 370,000 = women = on = age = of = menarche = revealed=>Low values (400 loci related to the timing of adolescence, Some overlap with well-known CHH genes, such as TACR3 and GNRHR (251).Of pathogenic variants in known CHH genes and the presence of oligogenicity. Approval of these results with larger studies is required and could lead to wider use of genetic testing to supplement clinical and biochemical data for diagnosis of adolescent CHH. Transient shortage of GnRH: FHH is similar to CDGP (see above), it is difficult to differentiate between CHH and CHH. FHH is a reversible form of GnRH deficiency, often induced by stresses such as caloric deficits, psychological distress and/or excessive exercise (278, 279). In adolescents, the frequency of FHH increases [3% to 5% of the population among young women (280)] and can be expressed as a lead artist (281), further complicating its distinction from CHH. There is a genetic sensitivity in the inhibition of the HPG axis in the presence of predisposing factors, and a common genetic basis of CHH and functional hypothalamus anonymization in degree women (282). For both sexes, malnutrition due to organic disorder such as celiac disease, inflammatory bowel disease (e.g., Crohn's disease, ulceration colitis) or other chronic inflammatory and infectious conditions should be ruled out as the primary underlying cause of a patient's HH before processing a diagnosis of CHH (7). Opioid-induced HH use is a major cause of functional/reversible HH in males and females (283, 284). In the central nervous system, endogenous opioids inhibit release of GnRH pulsatile (285) and suppress LH secretion, resulting in low sex steroid production and clinical hypogonadism (284, 286-288). Opioid misuse and addiction is an ongoing and rapidly evolving crisis in public health (289). It is therefore likely that the prevalence of HH associated with the consumption of these drugs will increase and become a growing diagnostic problem, especially among adolescents and young adults. HH associated with late-stage metabolic defects HH is associated with metabolic syndrome, obesity, and/or diabetes (290). Unlike CHH, this disorder is characterized by mild GnRH deficiency, which usually occurs after puberty (290). Obesity-related HH physiology is versatile and depends on the severity of the underlying metabolic defect (291). Decrease of SHBG is the main factor responsible for low T levels in men with moderate obesity, while men with severe obesity (BMI >40 kg/mer) display a low amount and reduced free T GnRH induced LH pulsatility (291). Increased aromatization of T to E2 in fat tissue with improved negative feedback afterwards, insulin resistance, and hypothalamus inflammation are considered causal factors that alter the function of GnRH neurons and/or vasodroid gondotrop cells (292). In particular, with the increasing incidence of childhood obesity, obesity-related HH is also on the rise in early adolescence, In boys, and nothing to characterize her in delayed sexual maturity (293-295). HH-related hemochromatosis hemochromatosis is part of the difference diagnosis for CHH, as it can often cause HH without further deficiencies in the pituitary gland and often preceeds heart and hepatic abnormalities (296). Juvenile momomatomatosis (type 2A) can present with delayed adolescence or hypogonodropial hypogondropial puncture due to mutations in hemojablyn (297, 298). The chromatosis is confirmed by measuring serum of iron, ferritin, and transmission promotes molecular diagnostic saturation (299). The family history of the neuromatosis also points to this etiology. It is important not to miss the diagnosis of the knownomatosis, as a reversal of the associated HH may occur after recurrent phlebotomy (300). Treatment of CHH with appropriate HRT, patients with CHH can develop secondary sexual characteristics, maintain normal sex hormone levels and healthy sex lives, and achieve infertility. There are several treatment regimens with different administrative paths. Choosing the treatment depends on the therapeutic goal, the timing of the treatment and the personal preference of each patient. It is important to know that randomized controlled trials on CHH hormone therapy are rare, and data on clinical observational studies are also limited. There is no uniform treatment regimen in international use. The pros and cons of available treatment regimens are summarized in Palmert and Dunkel (6) and Dunkel and Quinton (301) and tables 4 and 5. Table 4.Medical Treatment of Adolescent Induction, Hypogonadism, and Fertility in Female Patients with CHH Treatment. Menon and Administration. Advantages. Disadvantages. Induction of puberty in girls 17μ-estradiol (tablets) Initial dosage: 5 μg/kg daily natural oral estrogen is less preferable than transdermal pathway ♥ 5 μg/kg thyms every 6-1 12 mo to 1-2 g/d 17μ-estradiol (patch) Intl dosage: 0.05–0.07 μg/kg, only natural estrogen nocturnal small dose repair is not available; Should cut the patch of 25 μg/24 h ♥ to 0.08–0.12 μg/kg each 6 mo no liver transition (reduce thrombombolic risk) up to 50–100 μg/24 h extra progesterone after full breast development or breakthrough bleeding, During the last 14 d of menstrual cycle hypogonadism therapy in mature females Estroprogestin treatment (tablets) 17μ-estradiol 1 or 2 mag to mimic the changes in progestin physiological hormone: during the last 14 d of the month micron progestin at 200 meg/der uli, or dydrogesterone in 10g/d oral Estroprogestin treatment (patch or gell) 17μ-estradiol patch 50-100 μg/24 h daily, or mimic the changes in physiological hormone 17μ-estradiol 7.5–15 meg daily progestin: during the last 14 d of the micro progestin month at 200g/d through the way , or dydrogesterone in 10, Oral treatment of fertility in adult females Pulsatile GnRH IV pump: 75 ng/kg per pulse every 90 minutes Most physiological treatment is

not available in many countries adjusted dosage based on response, Up to 500 ng/kg per heart rate option to adjust pulse frequency in pump IV required central with SC pump specialty: 15 μg per heart rate every 90 minutes High success rate Risk of phlebitis treatment IV (rare) Dose adjusted based on response, up to 30 μg per pulse Less risk in resistance to the pituitary gland Multiple pregnancy (rare) Luteal phase: continue pump GnRH, Or hCG 1500 U every 3d for three times Gonadotropins hMG (FSH+LH) 75 to 150 IU SC daily, adjusted dosage based on follicle growth available worldwide in a more expensive induction of ovulation by hCG 6500 IU SC self-injection and higher risk of luteal stage overstimulation : Requires close monitoring of E2 and ultrasound hCG 1500 U every 3d for three times higher risk of multiple pregnancy progesterone 200 mags intra-vaginal daily table 5.Medical treatment of adolescent induction, Hypogonadism, and fertility in male patients with CHH treatment. Menon and Administration. Advantages. Disadvantages. Induction of puberty in boys T enanthate initial dosage: 50 mg IM monthly standard treatment with long clinical experience early epiphyseal closure (high dose) ♥ 50 mg converters every 6-12 Aromatizable mo to E2: Promote bone maturation can inhibit TV and sperm up to 250 mg/mo impact on future infertility unknown Gonadotropin hCG: Initial dosage 250 ICG SCU Twice a week, stimulate growth in spermatogenesis TV not standard treatment ♥ 250–500 IU bargains each 6 mo pre-FSH treatment can be beneficial in patients with TV <4 mel or history of cryptorchidism needs good compatibility in adolescent patients up to 1500 IU three times weekly should studies in large cohorts rFSH: dosage 75-150 IU Hypogonadism treatment in adult males T enanthate 250g IM every 2 to 4 wk relatively cost-effective instant injection interval adjusted based on the T trop available worldwide SC pathway under investigation (302) self-injection T undecanoate 1000g IM every 10 up 14 wk cost-effective margin of highly variable care; Important T trope tracking adjusted margin based on rarely trope T injections by nurses T Gell 50-80g/d Non-invasive risk of transmission by skin contact fertility treatment in adult men Pulsatile GnRH SC pump: 25 ng/kg per pulse every 1 The 20 minutes most physiological treatment is not available in many countries and adjusted dosage based on Serum T requires centers with expertise up to 600 ng/kg per pituitary gland resistance pulse (rare) gonadotrophin hCG: dosage 500–1500 IU SC three times a week, Available /s The world is relatively expensive for rFSH adjusted dosage based on T troy for patients with absent adolescence (TV <4 ml): RFSH frequent injections: dose 75–150 IU SC three times a week, Pre-rFSH therapy increases the adjusted fertility prognosis dosage based on FSH serum, sperm count and neonatal therapy of CHH so far, and hormone therapy during the neonatal period is only applied in male patients exhibiting micropen/cryptorchidism and HH (34, 136, 203, 204, 206, 303). Parallel treatment is not offered in female patients, as the consequences of severe GnRH deficiency during the late fetal period and mini-adulthood in women are unclear. In male infants with severe GnRH deficiency, the main goals of hormone therapy are to increase fusion size and stimulate testicular growth. Early reports in 1999 and 2000 described the benefit of early androgen treatment in boys with CHH or CPHD (202, 303). T treatment can increase pearl size and stimulate testicular development.hCG treatment with or without a combination of GnRH's nasal spray has been shown to be effective in treating neonatal cryptorchidism and prepubertal boys (304, 305). This finding could represent another benefit of neonatal care of children with CHH, as cryptorchidism is a cause of poor prognosis for adult infertility and is also a risk factor for testicular malignancy. Alternatively, orchidhufaxia - surgery to move an aching testicle that has not been damaged into the scrotum - is the current treatment for the choice of crypto-sidism. Some publications indicate a detrimental effect of isolated hCG treatment in boys with cryptorchidism (306). Concern for high-dose hCG treatment is its negative effect on germ cells with increased apoptosis, and therefore negative consequences for future infertility (306). However, the adring effect of hCG has not been shown in men with CHH with cryptorchidism. In 2002, Primary et al(203) reported the effects of sub-cutaneous injections (SC) of rLH and rFSH during the first year of life in a baby with CHH born with micropenis. This treatment led to an increase in penis length (1.6 to 2.4 cm), as well as a 170% increase in television accompanied by an increase in Inhibin B levels. Similarly, Bougnères et al(204) reported the use of gonadotropin in transfusion in two newborns, one was diagnosed with CHH and the other with CPHD. In this study, rLH and rFSH were administered sc using a pump for 6 months. This treatment not only repaired the microfenlis in both patients (8 to 30 mm and 12 to 48 mm, respectively), but also caused testicular growth (0.57 to 2.1 ml and 0.45 to 2.1 ml, respectively). LH and FSH serum levels increased to normal or supernatural levels, leading to endogenous secretion of T, inhibin B and AMH. Similarly, Sarfati et al(136) reported another case with perinatal diagnosis of KS based on the presence of the ANOS1 mutation (KAL1), Detection of kidney agenesis during fetal life, and the presence of micropenis at birth. The combined ionadotropin infusion from 1 to 7 months of age caused normalization of testicular size (0.33 to 2.3 ml) and penis length (15 to 38 mm). Recently, Lambert and Bognères (206) reported the effect of rLH combined rFSH injections in a series of eight male infants with CHH or CPHD. All patients presented with cryptorchidism or testicles are high in diagnosis and treated with a gonadotrophin infusion. Besides the increase in both fusion length and testicular size, the authors observed a complete testicular drop in six out of eight cases. However, the effect of combined gonadotrophin therapy on cryptorchidism in CHH babies will need to be formally evaluated by randomized controlled trials. Furthermore, the effect of such treatment on males with hypogonadism-free cryptorchidism remains unknown. Together, these studies show that gonadotrophin therapy combined in male patients with CHH during the preterm of the prey can have a beneficial effect on testicular endocrine function and genital development. This treatment may be superior to androgen therapy, as it stimulates the proliferation of Sertoli cells and the growth of nippy sammy tubes, as evidenced by the marked increase in television inhibin B serum concentrations (34). It is possible that the normalization of neon penis size will lead to normal adult penis size during the viralization of adulthood with exogenous T or hCG, thus preventing the feeling of discrepancy often reported by males with CHH with micropenis (147). At the same time, the increase in testicular size, which corresponds with the increase in Sertoli cell mass, can lead to better results in terms of sperm output during adolescent infertility induction or adulthood (34). Together, these data suggest that combined gonadotrophin therapy in men during the neon period may outsone the psychological effects of micropenis later in adolescence, and possibly improve fertility in adulthood. Therefore, randomized controlled trials with a greater number of patients are required to rigorously assess the effect of gonadotrophins on cryptorchidism in male newborns. Furthermore, longitudinal studies are warranted to determine the long-term benefits for reproductive function of hormonal intervention during infancy. However, there is no data to support such treatment in female patients with CHH. Adolescent induction induction of female secondary sexual characteristics and literature that focuses on induction of adolescence among teens (and adult women) with limited CHH. However, the therapeutic goals are well defined (7, 301, 307): to achieve breast development, to ensure external and internal genital maturity and other aspects of female appearance, and promote psychosexual development Respect for emotional life and sexuality (149). In addition, adolescent induction also increases uterine size, which is important for future pregnancy. Finally, optimizing growth to achieve a final height close to the expected parental average target is important, along with purchasing a regular BMD (301, 308). Most of the therapeutic regimens that move towards dementia in CHH are not based on evidence. Instead, they stem from expert opinion (7, 301, 309-311) in part due to the depleting of patients (308, 311-314). Furthermore, regimens have often mirrored turner syndrome treatment (315). Therefore, a dogmatic access should be avoided. We suggest that choosing the treatment combines the patient's opinion while maintaining a positive risk/benefit balance. In practice, E2 therapy (oral or transdermal) causes sexualization; However, the available protocols vary widely (312, 313). As transdermal estrogen in adulthood is associated with good efficacy profile and reduced cardiovascular events, it is unlikely to prioritize this formulation for adulthood induction (308). Additionally, a recent randomized trial in a small number of hypogonadal girls showed that transdermal E2 resulted in higher E2 levels and more effective feminization compared to incisive horse estrogen (314). Transdermal E2 management is often started at low doses (e.g., 0.05 to 0.07 μg/kg nocturnal, from 11 years ago), with the goal of mimicking E2 levels during early puberty. In older girls with CHH when breast development is a priority, transdermal E2 starts at 0.08 to 0.12 μg/kg (301, 308, 316). The E2 dosage should then gradually increase over the course of 12 to 24 months. After maximizing breast development and/or after breakthrough bleeding, cyclic progestian is added. In most females with CHH, estroprogestin therapy (EP) is effective to induce harmonious development of the breasts and genitals. In turn, the restoration of normal secondary sex characteristics probably contributes to a more satisfactory emotional and sexual life (149). Estrogen therapy also increases uterine size (133), and EP treatment causes monthly detox bleeding. However, this treatment does not restore ovulation. Finally, estrogen therapy causes a growth spurt and increases bone density in most female adolescents with CHH and older women with CHH (317). The treatment options are summarized in Table 4. Induction of male secondary sexual characteristics and therapeutic goals in adolescent males with CHH are also well defined: to induce masculinization, to reach optimal adult height, to acquire normal bone mass and body composition, to achieve normal psycho-human development, to achieve fertility. However, available treatment regimens may not always cover all of these aspects. Hormonal treatment options for induction of puberty in men with CHH are shown in the 5.As with girls with CHH and have of literature and a lack of randomized studies that equator the different treatment models, with only one randomized study including the number of patients with CHH (318). Difficulties also arise from studies accumulating heterogeneous cohorts of patients with CHH in terms of clinical presentation (i.e., degree of spontaneous puberty) and genetics. Early treatment is critical and usually involves injectable T-ester such as T enanthate (123, 301, 319). Pediatric endocrinologists treating younger patients (age 12) typically start treatment with low T doses (e.g., 50 mcg of monthly enanthate T) and gradually increase in dosage per full adult (250 mcm every 2 to 4 weeks) during ∼24 months. For patients with CHH seeking adolescent treatment later or early adulthood, a higher dose of T can be used to induce rapid masculinity. Initial T doses (such as 100 mcg of monthly enanthate T) can be rapidly increased to 250 mag intramuscularly (IM) monthly. Such regimes cause secondary sexual characteristics to maximize the final height (301, 320). Side effects for T treatment include erythrushitosis, premature closure of epiphysis (when doses are too high during the first year of treatment), and occasional erythema pain at the injection site. Note, T treatment does not stimulate testicular growth or spermatogenesis (123, 319), because intragonadal T production is required to stimulate spermatogenesis. Conversely, increased testicular growth during T therapy indicates the reversal in CHH and requires withdrawal therapy followed by a hormone profile (152). Induction of testicular maturation. Gonadotrophins are used for fertility treatments in older patients with CHH, but can also be used to cause adolescent puberty in adolescent men with CHH. Another benefit of gonadotrophin versus T treatment is the stimulation of testicular and semen growth. Therefore, gonadotrophin therapy may offer important psychological confidence in adolescents and improve self-confidence. Various treatment protocols including hCG alone or in combination with FSH were used to induce puberty in boys (321-325). In a retrospective analysis of boys with CHH, Bistritzer et al(321) showed a similar male effect of monthly T-injections and weekly hCG injections (5000 IU/wk), but testicular growth was significantly greater in boys treated with hCG.Rohayem et al. (325) Studied a relatively large group of adolescents with delayed adolescence, most of them with missing adolescence (n= 34). Adolescents received low-dose hCG (250 to 500 IU twice a week) with increasing ratings of 250 to 500 IU every 6 months, rFSH was added once the T serum achieved a targeted puberty level (5.2 nmol/L). This treatment led to a significant increase in TELEVISION (volumes of bites, 5 ± 5 to 34 ± 3 ml) and inspiration of spermatogenesis in 91% of patients Pre-treatment with FSH in adolescents with severe GnRH deficiency. The rationale behind pandering with FSH alone in patients with severe GnRH deficiency is that the mass of Sertoli cells is a predictor of future sperm output. FSH causes the spread of immature sertoli cells before maturing semi-nipper tube in rats (326), maca mullata (327), and probably in humans (328). In contrast, adult men with bial FSHR mutations demonstrate small testicular size and varying degrees of spermatogenesis failure (329). In addition, it has been suggested that patients with CHH with adolescence without puberty with/without micropenis and crypterchidism likely have complementary sub-optimal Sertoli cell due to a lack of mini-liberal, as evidenced by low levels of blood tom B serum, and therefore could benefit from a treatment coefficient with FSH. A study of 14 boys with gonadotrophin deficiency treated with priming rFSH showed significant increases in inhibin B and TELEVISION in the absence of an increase in intragonadal T production consistent with the proliferation of Sertoli cells (330). Spermatogenesis was obtained in six out of seven boys who provided semen samples, with a maximum sperm count ranging from 2.9 to 92 million/mel (median, 8.5 million/mel) (330). A subsequent randomized controlled study (see below) showed similar results in young adults (331). Therefore, pre-treatment with FSH before testicular maturation appears to compensate for the proliferation of sub-optimal Sertoli cells during late and miniliberal fetal life, and may therefore be beneficial in adolescent men for future fertility. However, this treatment is intense, requires frequent injections and close monitoring, and may not be optimal for all adolescent patients with CHH. A large multi-center study to assess the benefits and cost-effectiveness of pre-treatment with FSH in severe cases of adolescents and adults with CHH is warranted. Hypogonism therapy in male and female hormone therapy is required in adult females with CHH for maintaining bone health, increasing female appearance, improving emotional and sexual life, and promoting overall well-being. Studies on hormone therapy in older patients with CHH are limited and several centers prefer EP replacement therapy instead of birth control pills. Indeed, the effect of ethynylstradiol on the bone health of hypogonadal women is less established than the effect of 17μ-estradiol. Additionally, replacing long-term EP shifts BMD in another population of young hypogenic women with Turner syndrome (332). Recently, a randomized two-year trial comparing HRT versus birth control pills in hypogonadal women with primary ovarian dissent revealed a significantly higher BMD of the lumoteric spine in the HRT group (333). Additionally, there was no reported increased risk of thromboembolic events in women with CHH on EP replacement. E2 can be given By the way (dosage of 1 to 2 mag) or transdermally (50 μg daily by repair or 2 pumps of 0.06% per day) with a cyclic progestin regimen (i.e., micronized progesterone at 200 mcg or didrogesterone at 10 mcg, daily during the last 14 days of the cycle) to prevent hyperplasia in the blood mucous meth EP treatment causes monthly detox bleeding, but does not restore ovulation. This treatment should be maintained at least until the natural age of menopause. Males long-term androgen therapy is required in male patients with CHH to maintain normal T serum levels, libido, sexual function, bone density, and general loan. Various regimens of T replacement therapy are summarized in table 5.T can be given as an injectable formulation (aromatic androgen such as enanthate, cypionate, or undecanoate) or transdermal application (123, 319, 334). The maintenance dose of T is typically 250g of T enanthate IM every 2 to 4 weeks, 1 gram of T undecanoate IM every 3 to 4 months, or 50 to 80g of T-cell daily (table 5). Tracking troy serum T levels is important, as there is considerable variation regarding the metabolism of exogenous T products among patients with CHH (154). For T-injections, the frequency of injections should be assessed according to the measuring T troy serum, targeting the lower end of the normal range. IM T injections may cause significant differences between peak and tro0s T levels. Pilot studies have shown that weekly SC injection of low doses of T cypionate or T enanthate can result in a more stable profile of plasma T (302, 335). For patients treated with T-level, the target of random T-level serum is mid-normal range. The benefit of T-level is its pharmacokinetics with a more stable T concentration within the normal adult range, and a minimally invasive lack of injections. However, patients on T-level should avoid skin contact with others (partners or children), as there are known risks of hyperandrogenism in women (336) or simplified puberty in children (337). Among transdermal T's reported shortcomings are the high cost and lack of reimbursement in some countries. Whatever treatment is used, men with CHALLENGED CHH adhere to long-term care, and poor adherence may contribute to side effects on bone health, sexual, and psychological health (146). Infertility treatment induction of infertility in women with CHH infertility in women with CHH is caused by poor vascation secretion of both gonadotrophins, LH and FSH, leading to impaired ovarian stimulation. Specifically, GnRH deficiency leads to impairment of follicle terminal growth and adolescence, resulting in chronic ovulation. However, there is no evidence of a reduction in follicle reserve (132). This point should be emphasized to patients and their families once the diagnosis is marked. Indeed, the combination of small Decreased port follicle count, and low circulation AMH concentrations observed in women with CHH could inadvertently suggest a change in the poor fertility prognosis ovarian reserve (132). In contrast, these patients should be informed that ovulation induction will lead to a fairly good result in terms of infertility in the absence of a male cause of infertility or advanced age (>35 years) (132, 133, 338-340). Before considering ovulation induction, sono-hysterosalpingography or traditional hystero-pingography can be performed to assess both the integrity and cavities of the uterine cavity and fallopian tubes (341). Alternatively, sono-hysterosalpingography can be performed after several cycles of successful ovulation in the absence of pregnancy. In addition, a related male fertility factor should be ruled out by receiving semen surgery (340). Couples should be expected to have the optimal timing of sexual intercourse during the ovulation induction, since this front-row treatment does not require IVF (132, 133, 338, 339). CHH is one of the few causes of medical treatment of male infertility... The goal of ovulating induction therapy in female patients with CHH is to achieve mono ovulation to prevent multiple pregnancies. Ovulation can also be obtained with pulsatile GnRH treatment or irritation with gonadotrophins. The latter also includes extraction or rfsh treatment followed by hCG or rLH to activate ovulation (342). The therapeutic choice will depend on the expertise of each center and the local availability of the various medical treatments. GNRH Pulsatile treatment. Pulsatile GnRH treatment using pump was first proposed by Leyendecker et al. (343-345) to cause ovulation in women with various causes of hypogonadotrophic amanorea (who I am, ovulation). Given its exceptional efficacy in acquired forms of HH, Pulsatile GnRH was successfully applied to women with CHH (346) and other factors of acquired HH (347-349). Both sc and IV pathways for GnRH management are suitable to restore fertility (347, 350). Pulsatile GnRH restores the physiological secretion of the cerebral gonadotrophins, which in turn causes ovulation in patients with CHH (351-355). The main benefit of pulsatile GnRH therapy compared to gonadotrophin therapy is the decreasing risk of multiple pregnancy or ovarian overstimulation (347, 348, 355). As a result, it requires less monitoring and monitoring during treatment. Therefore, when pulsatile GnRH treatment is available within the treated area, it should be considered the first line of treatment in women with CHH, given that it is the most physiological regimen and results in fewer side effects. Physiologically, GnRH's heart rate intervals vary throughout the menstrual cycle, as evidenced by LH heart rate studies in a large series of women with regular (356). Based on this study, the frequency of GnRH pulses is set for every 90 minutes during the early follicle phase of treatment, and then accelerated every 60 minutes during the mid and late follicle phase. After ovulation, the frequency is reduced every 90 minutes. Finally, in the late luteal phase, there is a further reduction every 4 hours that will benefit FSH secretion across LH. However, gnRH pulsatile at a constant frequency of 90 minutes also causes maturation of the ovarian follicles, surge in LH and ovulation (350). The dosage of GnRH is required to restore normal ovulation and is well studied in females with chh or functional hypothalamus amenorrhea. IV doses of 75 ng/kg per pulse are considered a physiological dose to cause adequate cerebral gonadotrophin secretion and ovarian stimulation (357). In 30% of females with CHH, admissing the adjournence exists in the first cycle, requiring increased GnRH doses and longer stimulation (354). Once ovulation is achieved, the luteum corpus must be stimulated to produce progesterone, which is mandatory for fetal transplantation. The Pulsatile GnRH pump is able to maintain insufficient endogenous LH pulsatile secretion to ensure progesterone release by lotum corpus until endogenous secretion of hCG from placenta begins (355, 358). Another treatment option for luteal support is hCG (SC injections of 1500 IU every 3 days for three times), which is less expensive and well tolerated. The success rate of ovulation induction is excellent among women with CHH, reaching 90% ovulation per cycle, and 27.6% conception per ovulation cycle. The number of cycles needed to achieve pregnancy is quite variable, ranging from one to six cycles (350, 355). The rate of multiple pregnancies is slightly higher than the general population by 5% to 8% (357), but much lower than in the treatment of ionadotrophin. In particular, the Pulsatile GnRH pump can also be effective in the presence of GnRH resistance, such as in women with CHH who harbor partial loss mutations of function in GNRHR (351, 354). When administered to SC, higher doses (15 μg per heartbeat) are required, and usually the frequency of pulses are maintained in one every 90 minutes. The success rate is slightly lower in the rate of ovulation per cycle (359). However, the SC administration has no risk of phlebitis and is more favorable. GnRH heart pulse treatment is discontinued when pregnancy occurs, and no early pregnancy side effects have been reported (360). After several unsuccessful cycles of GnRH stimulation, gonadotrophin therapy should be offered (see below) (338, 339) to circumvent potential resistance to the brain ability associated with or not with loss of function in GNRHR mutations (197, 354). Gonadotrophin treatment. In women with CHH, ovulation can also be achieved with FSH treatment followed by hCG or rLH to stimulate ovulation. However, women with severe GnRH deficiency Gonadotrophin levels are very low, thus requiring both FSH and LH during the follicle phase. LH stimulates theca ovarian cells to produce androgen substrates, allowing sufficient secretion of E2 by adolescent follicles (132, 233, 338, 361). E2 is necessary for optimal endometrial thickness and cervical mite production, which in turn are necessary for sperm transfer and fetal transplantation (132). Typically, human menopause gonadotrophins SC (hMGs; FSH plus hCG) Doses of 75 to 150 IU/d are sufficient to cause ovulation. Typically, a dominant follicle (>18 mm) will mature ∼ 12 days. The initial dose of hMG is often increased or decreased depending on the ovarian reaction, as estimated by repeated Serum E2 measurements or through ultrasonography counting and follicle reciprocity maturing every other day. This regimen minimizes the risk of hyperstimulation syndrome of multiple pregnancy and ovaries. After ovulation, progesterone production can be stimulated by repeated hCG injections, or direct management of progesterone during the postombiotic phase by the end of the luteal phase. IVF. If conception fails after repeated successful induction of ovulation in females with CHH, IVF may be an alternative (362, 363). Infertility induction in men with CHH CHH is one of the only causes of medical treatment of male infertility, and fertility treatments have very good results. Infertility induction can be performed either by long-term pulsatile GnRH treatment or with an integrated gonadotrophin treatment. GNRH Pulsatile treatment. Pulsatile GnRH treatment is a sensible approach in patients with CHH seeking infertility. Physiological GnRH secretion is episodic, so GnRH therapy requires IV or SC GnRH administration in a pulsatile way using a mini infusion pump (364). This treatment will stimulate the secretion of the adebral gonadotrophin, in turn producing intra-gondilly T, resulting in the initiation and maintenance of spermatogenesis as evidenced by increased TV and sperm output by 12 months of treatment on average. The common initial dosage is 25 ng/kg per beat every 2 hours, with subsequent titotion to normalize normal range T serum for adults (66, 365-367). Response to treatment varies depending on the degree of lack of GnRH, with normalization of TV and successful induction of spermatogenesis for all patients with partial puberty. On the contrary, tv and sperm counts are lower in patients with absent adolescence, and 20% of these patients remain aesperami despite 12 to 24 months of pulsating GnRH treatment (66). A systematic literature review on this topic appears in Table 6 (66, 250, 325, 330, 364, 366, 368-402). Table 6.Fertility Outcomes in Male Patients with CHH: Summary of 44 Studies Published in Study No. CHH (n) . Venomat and Venomat Kass.c (n). CHH with crypto-chidism (n). Median BASE TV (mL). Median ציון .(מל/106) ספירת זרע מרבית . (מל) טלוויזיה TTS (אזוספרמיה מתמיד) כשל בטיפול . (מו) (n) . הריונות . טיפולים בשימוש (n) . שופטים . . Combined gonadotropin therapy 1 10 8 2 NA NA NA NA 16 1 hMG + hCG 4 (368) 2 36 25 11 NA NA NA 5.1 5 9 hPG 12 (369) 3 15 7 8 7 NA NA 8.5 10 5 hMG + hCG 8 (370) 4 13 7 6 4 2.4 6.9 1.3 11.5 1 hMG + hCG 2 (7) (371) 5 13 13 0 0 1.2 3.1 3.0 NA 2 hMG + hCG 3 (372) 6 24 17 7 Excluded 6.8 13.9 16.7 7.6 Not included hMG + hCG 22 (250) 7 8 NA NA NA 2.1 9 1.0 24 2 hMG + hCG 1 (8) (373)+ 8 18 9 9 5 2.5 8 4 12 9 hMG + hCG 1 (374)++ 9 16 8 8 4 3.5 13.3 6.0 23.1 2 hMG + hCG NA (375) 10 18 NA NA Excluded 3.7 14.9 2.6 34.2 4 hCG + hMG 7 (10) (376) 11 10 4 6 Excluded 4 12 18.5 24 NA hMG + hCG 3 (4) (377) 12 7 6 1 6 1.2 9 10.0 11.8 1 hMG + hCG 3 (378) 13 9 7 2 0 2.2 8 8.0 14 2 hMG + hCG 4 (379) 14 26 12 14 13 1.5 3.8 2.2 12.2 12 hMG + hCG 3 (380) 15 35 19 16 Excluded 4.3 11.1 14.0 5 12 uFSH + hCG 1 (4) (381) 16 27 16 11 Excluded 3.6 10.5 16.5 9 3 uFSH + hCG 2 (10) (382) 17 18 9 9 8 4.4 15.3 1.2 6 2 hMG + hCG 3 (383)+++ 18 10 8 2 Excluded 3.5 9.6 5.0 6.6 2 rhFSH + hCG 2 (384) 19 26 17 9 Excluded 2 12 1.5 9 4 rhFSH + hCG 4 (7) (385) 20 20 13 7 5 8 NA 5 5.5 NA rhFSH /uFSH + hCG NC (386) 21 9 8 1 4 3 7.5 5.1 16.8 NA hMG + hCG NA (387) 22 26 11 15 11 5.7 12 5.0 7 10 rhFSH + hCG NA (388) 23 23 18 5 9 1.6 4.85 1.0 52 7 hMG + hCG NA (389) 24 4 4 0 0 4.1 6.8 2.05 12 0 hMG + hCG 3 (390) 25 4 2 2 2 1 5.5 3.0 10 1 rhFSH + hCG NA (330) 26 25 16 9 Excluded NA 14 5.2 5.1 1 rhFSH + hCG 5 (30) (391) 27 77 48 29 Excluded 3.4 11.7 8.2 18 13 rhFSH + hCG 14 (51) (392) 28 51 34 17 12 6.5 NA 8.0 23 NA rhFSH/uFSH + hCG 38 (393) 29 10 9 1 0 NA 9 7.0 9.8 1 hMG/rhFSH + hCG 4 (394) 30 31 22 9 Excluded 3.8 9 22.8 12 NA rhFSH/uFSH + hCG 10 (22) (395) 31 19 8 11 9 4.5 10.2 7.1 11 1 hMG + hCG 5 (11) (396) 32 223 112 111 40 2.1 8.1 11.7 15 80 hMG + hCG 17 (397) 33 38 18 20 19 2.5 16.5 15.0 55 3 rhFSH + hCG 0 (325) 181 190 158 358 515 899 תתת-תום Pulsatile GnRH 2 3 5 34 טיפול NA 3 4.5 4.1 3 GnRHb 1 (364) 35 10 6 4 NA NA NA 4.2 12 1 GnRH 3 (398) 36 30 NA NA 0 5 18 68 5 1 1 24 3 GnRH 2 (5) 37 5 NA NA NA 2.4 11.5 0.1 24 3 GnRH 2 (5) (373)+ 38 1 0 8 2 1 4 14 19.2 12 0 GnRH NA (366) 39 18 10 8 4 2 10 4.7 5 4 GnRH 1 (400) 41 6 4 2 3 6.8 14.9 1.6 4 1 GnRH 3 (383)+ 42 52 26 26 21 3.3 12 15.0 24 9 GnRH NA (66) 43 35 12 2 3 9 2.3 9 NA 12 9 GnRH NA (401) 44 20 9 11 4 2.9 10.8 14.2 15.6 NA GnRH 5 (14) (402) Subtotal 219 95 89 55 38 36a Total , n 1118 610 447 213 228 217a Average 3.4 9.8 7.59 15.3 Weighted Average 3.51 10.8 9.83 15.2 Gonadotrophin Treatment. Gonadotrophin therapy (hCG alone or in combination with rFSH) is another treatment option for infertility induction in male patients with CHH. While IM injections have previously been prescribed, SC gonadotrophin injections are now preferred, and different formulations are used. Typical doses vary from 500 to 2500 IU two to three times a week for hCG, and from 75 to 225 IU two to three times a week for FSH preparations, hMG tools, highly purified urine FSH, or rFSH. Dosage of hCG adjusted based on T troy serum, rFSH dosage is titrated based on serum FSH levels and sperm count. Fertility outcomes in men with CHH. From the early 1970s to 2017, a series of 40 papers were published responding to fertility and sperm in patients with CHH, and included >1000 patients with CHH (Table 6). More than 80% of patients were treated by combined gonadotrophin therapy. Although the GnRH pump is an effective treatment to cause spermatogenesis in the absence of a pituitary gland defect, the significant use of gonadotrophins may indicate that GnRH treatment is not available in several countries, including the United States, where it has been primarily used only in a research environment. Furthermore, this treatment is expensive and likely less convenient than gonadotrophin injections given the long period (1 to 3 years) should ripen the testicles. Both GnRH pulsatile and gonadotrophin therapy are effective to cause spermatogenesis and fertility in men with CHH (403-405); However, no clear superiority of GnRH compared to gonadotrophins was observed. Similarly, none of the products available in FSH look different in terms of sperm output. The overall success rate in terms of sperm output varies across studies (64% to 95% success), with sperm counts ranging from zero to several hundred million per milliliter. The average median weight time to achieve sperm production was just over a year (Table 6). It is well established that even low sperm concentrations in men with CHH are enough to fertilize partners (250). Pregnancy was successfully achieved in 175 partners of patients with CHH (table 6), and successful pregnancies were reported in 16% to 57% of patients with chh fertility want. As reported (Table 6), most of the pregnancies achieved were by natural conception. In the minority, IVF was necessary due to the existence of the ovation or uterus in a kettle in a partner (see References cited in Table 6). In contrast, 192 patients failed to produce sperm despite long-term gonadotrophin treatment (median, 24 months), corresponding 12% to 40% depending on the study. In patients with azospermia after treatment or poor sperm quality, more invasive treatments such as testicular sperm production were suggested followed by intracytoplasmic spermatozoid injection (390); However, the results are not clearly described in these studies. The main limitations of most studies are (i) the size of the small population often; (2) the inclusion of all types of patients with HH (i.e., severe, partial, or AHH, which are known to have different outcomes in terms of infertility); (iii) inclusion or exclusion in certain studies of men with cryptorchidism with varying dates of postpartum surgery that can also affect prognosis; (4) the lack of studies that take into account genetic mutations as a predictor of treatment outcomes; and (v) the absence of potential randomized studies that equator gonadotrophin treatment head-on to treat Pulsatile GnRH. Despite these limitations, there are some lessons to be learned: (1) Sperm count may improve but rarely normalize in patients with CHH based on WHO criteria; (2) Low sperm concentration does not always prevent infertility in men with CHH; and (iii) a number of predictive factors have been found in this population: testicular volume. TV is an indicator of the degree of lack of GnRH and is a positive predictor of sperm output (66). When we consider the entire population of patients with CHH treated for infertility (n=994), the average testicle size was 3.5 ml at the base and increased to 8.6 ml by the last visit. However, the spectrum of television at the base varies widely within and across studies. Therefore, it is not surprising that studies including patients with milder forms of GnRH deficiency had the best sperm output (Table 6). In contrast, studies in which most men with CHH exhibited pre-guild testicles tended to get the poorest results. These patients generally lack the beneficial stimulant effects of running a gondotroff during mini-puberty and can benefit from a treatment coefficient with rFSH before GnRH [see below (331)]. Crypto-sidism. The presence of unilateral or unspeed bilateral testicles reflects the severity of the lack of a gondotrop axis, and is therefore one of the main features of prenatal GnRH deficiency. Cryptorchidism is recognized as a negative predictor of sperm output, and patients with bilateral cryptorchidism have lower sperm counts than those with a one-sided version or those without cryptorchidism. Also, patients with cryptorchidism require more time to obtain spermatogenesis (66). Although >1000 men with CHH included in various studies focusing on spermatogenesis/infertility, only 19% had cryptorchidism. Furthermore, at 42% Studies excluded patients with crypto-sidism. Furthermore, 30% of the studies did not explicitly include cryptorchidism because of the expected poor spermatogenesis prognosis. A number of factors may be involved in germ cell depletion associated with cryptorchidism, including apoptosis of germ cells in a test that remains too long in the gut (406). In this setting, surgical repair should be recommended for 6 months to 1 year of age (407). Early exposure to androgens. A single study considered androgen therapy was promoted to be associated with poorer prognosis (393), but this result was not replicated in the following studies (66, 389, 397, 408, 409). Therefore, the effect of previous androgen treatment on infertility remains controversial. HRT is the first treatment for CHH-asociated bone loss... Pre-treatment with FSH. The fertility result with GnRH or classic gonadotrophin therapy is sub-optimal, especially in patients with severe GnRH deficiency. In 2013, a randomized study investigated the addition of rFSH pretreatment to standard GnRH pulsatical treatment in 13 young adults with severe GnRH deficiency (TV <4 ml) and no previous gonadotrophin treatment (331). Patients with cryptorchidism were not included in this study. After 4 months of rFSH alone, average TV doubled from 1 to 2 ml in the absence of increased intra-gondelli T with a concurrent increase in inhibin B levels into the normal range. Furthermore, histological findings have shown an increase in the diameter of cminyperus tubes compared to base without any sign of puberty, as well as improved proliferation of childish Sertoli spermatogonia cells (331). After 2 years of pulsatile GnRH, both groups (with and without pretreatment rFSH) normalized Serum T levels and demonstrated significant testicular growth. All patients in the pre-treatment group developed sperm in their palette (compared to four out of six in the GnRH group only) and showed trends towards higher maximum sperm counts, TVs, and sea serum levels B, although this did not reach statistical significance primarily due to the small sample size. Therefore, larger potential multi-center studies are needed to support the supremacy of early treatment with FSH before classic treatment (GnRH or hCG plus FSH) on improving fertility outcomes in patients with severe GnRH deficiency, with and without cryptorchidism, and assess the effective cost of pre-treatment with FSH. Management of adverse adverse health events related to CHH bone loss and fractures in a recent mixed longudinal study of 2014 healthy children significantly improved our understanding of skeletal development. McCormack et al (410) showed that (i) at 7 years old, healthy children achieved only 30% to 38% of the entire body's mineral content observed (BMC); (2) During adolescence, there was a significant gain in BMC; (iii) The average age at a record rate of the entire BMC There was 14.0 years in boys, and 12 to 12.5 years in girls, which was, on average, 0.6 to 1.2 years after PHV; and (d) another 7% to 11% of the maximum observed BMC achieved after linear growth ceased. The relative roles of androgens and estrogens in bone metabolism in bone health have recently been studied in adult men. Endogenous sex steroids were suppressed with goserelin acetate, and patients were then treated with increasing doses of T only, or in combination with anastrozole aromatase inhibitors to suppress conversion of T to E2 (411). The results of this study showed that bone absorption increased considerably once E2 levels were low, even when the T serum was significantly higher (411). Deficiency in E2 mainly affected the cortical bone. Cuts of <10 pg/mL for E2 and <200 ng/dl (6.9 nmol/L) for T (with complete aromatics) were suggested as undesirable for bone health (411). Consistent with these figures, low BMD exists in most patients with CHH. However, important variance exists regarding the degree of bone involvement in CHH, as described by a recent report of older patients who have not been treated with CHH with low to near-normal BMD and there is no significant difference compared to patients treated by HRT (412). These data suggest that the beneficial effect of sex steroid replacement therapy on bone condition in this specific population may be smaller than previously thought. However, the authors could not completely rule out the possibility of previously old casual hormone therapy never being treated for CHH. Similarly, they could not rule out the possibility of sub-optimal adherence to chronic hormone therapy in patients treated with CHH. Bone remodeling is low in CHH, as suggested by the only study that performed bone biopsies chisel Ilyak in patients with low bone mass CHH (413). Data on bone remodeling markers are inconclusive and not always compatible with BMD (414). Evidence on fracture incidence is rare, with some reports of accidental vertebrae fractures but no comparison of the prevalence against controls (414, 415). HRT is the first-line treatment of bone loss associated with CHH, with anti-fertility drugs (bisphosphonats, denosumab) as second-line therapeutic choices (416). Given the male sex control of CHH, the effect of gondal steroid replacement has been primarily studied in men receiving T and/or gonadotrophins. T increases BMD in CHH (413, 417) and mixed hypogonadal cohorts (418-421). Increased levels of bone formation markers such as P1NP, usually observed early in treatment, may reflect the anabolic effects of androgens (422, 423). It is not yet clear whether the T replacement fully reverses the bone phenotype (418) or only partially improves BMD (417). Age at the beginning of HRT may be a crucial prognostic factor for a therapeutic response. In the first study to investigate A link between CHH and bone, Finkelstein et al(413) described bone densities measured by CT in 21 men with CHH, of which 15 initially fused epiphyses and 6 had open epipsies. Most patients received androgen treatment first. After bringing T levels within the normal range, the young group increased both cortical and terbacular bone densities, while those with epiphyses initially merged exhibited only an increase in cortical bone density (413). The authors hypothesis that this difference reflects the physiological bone aggregation that occurs during normal puberty. This data suggests that there is a critical period of skeletal response to sex steroids, which will further highlight the importance of timely diagnosis of CHH. Nevertheless, another study focusing on older patients with CHH (a median age of 56 years) revealed a significant response to bone replacement T despite delayed diagnosis and the on start of HRT (141). Therapeutic adherence may also explain the variance observed. Stressing the importance of HRT compatibility, Laitinen et al (414) demonstrated that prolonged breaks in HRT (>5 years in total) were associated with decreased BMD in the lumline spine, hip, hip neck, and entire body, although no difference in fracture incidence was observed. Note that certain genes involved in CHH may also have direct implications for bone health, which may confuse the reported results from a small series of men with CHH. Specific genetic factors that may directly affect the bone include mutations in FGF8, FGFR1 and SEMA3A (182, 424). Despite the importance of estrogen for the male skeleton, measurement of E2 is not routinely performed in patients with CHH with bone defects. This approach is based on the fact that standard T treatment is aromatic and corrects low estrogen levels (212). However, this should be considered in cases with a sub-optimal response to HRT and after excluding more frequent factors such as poor compatibility. Like other causes of secondary osteoporosis, adequate calcium intake (>1000 mg/d) should be guaranteed. Vitamin D deficiency is common in the CHH population (415) and must also be corrected. Targeting levels >30 μg/L (75 nmol/L) likely in the presence of low BMD. A small retrospective study suggested that central hypogonism as seen in CHH may lead to worse bone outcomes compared to primary hypogonadism regardless of blood gland steroid levels (425). The authors assumed that severe vitamin D deficiency in CHH is due to decreased LH dependent on vitamin D and 25-hydroxylation in the testes. Neverth caption, no difference was detected in vitamin D levels in a larger group of patients with CHH compared to age-compatible and BMI-compliant controls (426). Further studies we have commented on this problem should focus on removing the shearing of seasonal variation of vitamin D. Metabolic defects are In patients with CHH, are generally thought to be secondary to sex steroid deficiency (292, 427). The incidence of overweight and obesity in patients with CHH is between 40% and 50% according to the latest italian nationwide group of patients (134), similar to the general Italian population (428). However, another study identified a pre-high value of metabolic syndrome in CHH compared to the general population (429). The latter compared 332 young patients with CHH without prior androgen therapy compared to 395-year-old and BMI-compliant controls and discovered a significantly increased incidence of all components of metabolic syndrome (i.e., waist circumference, arterial blood pressure, fasting glucose, homeostical model assessment of insulin resistance, serum triglyceride levels). T treatment with CHH leads to an improvement in insulin sensitivity (430, 431), decreased C-reactive protein levels in high sensitivity (430) and low density lipoprotein cholesterol (432), as well as increased lean mass and decreased visceral fat test (431). Furthermore, short-term withdrawal of T treatment in male patients with CHH causes moderate insulin resistance and increased fasting glucose levels (427). Similar to treating T in male patients with CHH, gonadotrophin replacement therapy is accompanied by increased lean mass, reduced body fat and waist-hip ratio, increased sensitivity to insulin, and reduced triglyceride levels (433). It is possible that the genetic determination factors predisposed some patients with CHH to metabolic disorders. Leptin deficiency or resistance leads to faulty signaling of various metabolic cues to the hypothalamus, which typically regulates both energy homeostasis and reproductive ability (434). Recently, the FGF21/KLB/FGFR1 pathway was also featured as an important player underlying the relationship between reproduction and metabolism (253). In this study, most probands with CHH harboring KLB mutations (9 of 13) demonstrated some degree of metabolic defect (i.e. overweight, insulin resistance, and/or dyslipidemia), consistent with the potential role of this pathway in metabolic health. Conclusions Despite a set of relatively simple diagnostic criteria, chh's phenotype spectrum is broad. This includes a prominent portion of reversal cases, overlap with common reproductive disorders such as CDGP and FHH, and the presence of CHH as a component of more complex entities such as CHARGE and Waardenburg syndromes. Timely diagnosis is critical; However, the clinical presentation and biochemical profiles are often not fully informative in early adolescence, as chh's presentation is very similar to that of CDGP. One possible opportunity for an earlier diagnosis is during a mini-puberty, but today the importance of evaluating mini-polybarti is unknown. The progression of biochemical tests with minimal blood samples (e.g., dry spots in the blood) suggests To evaluate the HPG axis function in the off-label in normal situations and diseases. Finally, the discovery of genes involved in GnRH ontogeny helped clarify pathophysiology as well as improve genetic counseling of the disease, and helped process an accurate diagnosis. The emergence of high throughput sequencing technologies has significantly increased the detection of rare variants. However, the result is a specific challenge to classify for pathogenicity, especially in the context of olygogenicity seen in CHH. Large multinational studies are required to define CHH genetic risks related to the spectrum of rare variables. Hypogonadotropic abbreviations adolescent hypogonadotropic combined with the brain adjunct hormone lacks double energy X-ray absorption functional hypogonadotropic hypogonadism Genome Society human hypogonotropin study hypogonotropin hypogonutropin human gonadotrophin human hypothalamus-The brain-gondal hormone replacements hypogondetic hypogondetic hypogonadi hypogonadotropic the World Health Organization recognizes financial support: this work was supported in part by the Hospitalier de Recherche Clinique Hypo-Proteo program, assisting Publique Hôpitaux de Paris, and the Ministry of Health (J.V.); The Livelihood Agency de Lotte Contra La Dufage (French Anti-Doping Agency) (for J.J.); affection for shedding la Recherche Medica Grant FRM-2009 (for J.J.); University of Paris-Sud (Qualité Recherche bonus) (for J.J.); U.S. National News Agency Grant ANR-09-GENO-017-01 (for J.J.); Hospitalier de Recherche Clinique Program, French Ministry of Health Grant P081216/IDRCB 2009-A00892-55 (Waritah), Assistance Publique Hôpitaux de Paris (to J.Y.); The Children's Research Foundation, the Academy of Finland, the Sigrid Youselius Foundation and research funds of helsinki Central Hospital (T.R.); and the Swiss National Science Foundation Grant SNF 31003A 153328 (N.P.). Discovery Summary: Authors have nothing to reveal. Recommendations 5. , , , , , , . The timing of normal adolescence and the age limits of pre-sexual orientation: variations around the world, secular trends and post-immigration changes. . ;():–.7. , , , , , , , , , , , , , , , , , . European consensus statement on congenital hypogonadotropic hypogonadoidism – pathogenesis, diagnosis and treatment. . ;():–.8. , , , . LH serum and FSH responses to repeated administration of gonadotrophin-releasing hormone in patients with hypogonadotropic hypogonadotropic idiopathic. . ;():–.11. , , , , , , . Paternity matches HLA in two fertile eunuchs with hypogonadotropic congenital hypogonadotropic and anosmia (Kalman syndrome). . ;():–.15. , , , , , , , . Defective migration of neuroendocrine GnRH cells in humans Conditions. . ;():–.16. , , , . Evidence that cells expressing hormone-releasing hormone mRNA refuge hormone in the mouse are derived from the ancestral cells in the olfactory placod. . ;():–.18. , , , , , , , , , , , . The evolution of neurons that control fertility in humans: new insights from 3D imaging and a transparent fetal brain. . ;():–.22. , , , , . Studies on human sexual development. II. Gonadotrophin fetal serum and mama and sex steroid concentrations. . ;():–.23. , , , , . Studies on human sexual development. III. Fetal cerebral and serum, and amniotic fluid concentrations of LH, CG, and FSH. . ;():–.26.27. , , , , , , , , , , . Maturation of hypothalamus-parasitical-gondal function in normal human embryos: circulating levels of gonadotrophins, their alpha-subunit and free testosterone, and a mismatch between immune and biological activity of the follicle stimulant hormone in the cycle. . ;():–.28. , , , , . Gonadotrophins, prolactin, tom A, inhibin B, and activin A in human fetal serum from mid-pregnancy and pregnancy term. . ;():–.29. , , , , , , , . Negative regulation of FSH/LH fetus at the end of pregnancy is associated with kisspeptin/KISS1R expression rejected in tuberal hypothalamus. . ;():–.31. , , , , , , , , , . Direct interaction of SRY-related SOX9 protein and causes steroid 1 regulates transcription of the human gene against the hormone molyrian. . ;():–.33. , , , , , , , . Development and reduction of testicles in relation to crypto-sidism. . ;():–.34. , , , , , , . Treatment of newborn gonadotrophin in male congenital hypogonadotropic beautifying. . ;():–.37. , , , , , . The development of human fetal ovaries involves the spatiotemporal expression of the p450c17 protein. . ;():–.38. , , , , , , . Sex differences in serum luteinizing human hormone and neon testosterone in the first few hours after birth. . ;():–.41. , , , , . Hypophysio-bluttal function in humans during the first year of life. 1. Evidence of testicular activity in early infancy. . ;():–.42. , , , , . Pituitary-pituitary ratios in infancy: 2. Patterns of steroid concentrations in the serum gland in a person from birth to age two. . ;():–.43. , , , , , , , . Longitude reproductive hormone profiles in infants: Record of inhibin B levels in infants exceeds levels in adult men. . ;():–.44. , , , , , , , , . Activating ovaries after birth has effects in target tissues and estrogen in infants. . ;():–.45. , , , , , , , , , . A time trajectory of wave gonadotrophin serum, inhibins, an antimolarian hormone in newborn males during the first month of

life. . ;():–.46. , , , . Sexual dimorphism in gonadotrophin levels after birth in infancy reflects a varied maturation of ovarian hormone synthesis and occipitation. . ;():–.48. , , , , , , . Testosterone measured in infancy predicts subsequent sex-type behavior in boys and girls. . ;():–.49. , , , , , , , . Developmental changes after birth in the cerebral-ovarian axis at pre-age and the term babies. . ;():–.50. , , , , , , , , , , , , . Changes in antimolarian hormone (AMH) throughout lifespan: a population-based study of 1027 healthy men from birth (umbilical blood) up to 69 years of age. . ;():–.55. , , , , , , , . Physiological androgen insensitivity of the fetus, newborn, and early infantile examination is explained by the rubbing of androgen receptor expression in sertoli cells. . ;():–.56. , , , , , , , , , , , . Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-molecular hormone suppression during early human testicular development. . ;():–.57. , , , , , , , , , , . Gender difference in breast tissue size in infancy: Correlation with estradiol serum. . ;():–.58.59. , , , , , , , , . The pattern of gonadotrophin secretion in anarchic boys from birth to adulthood: pathophysiological aspects and diagnostic usability. . ;():–.61. Junior. The role of previous puberty development, biochemical markers of testicular maturation, and genetics in the phenotypic heterogeneity of idiopathic hypogonadism. . ;():–.62. , , , , , , , , , , , , . Insulin-like peptide 3 (INSL3) in men with congenital hypogonadism/Kalman syndrome hypogonadism and effects of different ways of hormone therapy: a single center study of 281 patients. . ;():–.63. , , , , , , , , , , ; American urological asphyxiation. Evaluation and treatment of crypto-sidism: AUA guideline. . ;():–.64. , , , , , , , , , , , , . Difference in the incidence of congenital cryptorchidism in infants between two Nordic countries. . ;():–.65. , , , , , , , . Prevalence, phenotypic properties and molecular genetics of Kalman syndrome in Finland. . ;():.66. Junior predicts the result of long-term GnRH treatment in men with idiopathic hypogondotism hypogondism. . ;():–.68. , , , , , . Ontogeny's pulsatile gonadotrophin releases hormone secretion from mid-childhood, through adolescence, into adulthood in humans: research using de-evolution analysis and ultra-sensitive immune mass. . ;():–.69. , , , , , , , , , . Gonadotrophin-releasing hormone: One polypeptide regulates the secretion of follicle-stimulating hormones. . ;():–.70. , , , , , , , . Human adolescence. Simultaneously increased secretion of hormone and testosterone to The Whitney during sleep. . ;():–.71. , , , , . Patterns of pulsating hormone secretion luteinizing before and during the onset of puberty in boys: research using immune assayag. . ;():–.72. , , , , , , , . Developmental changes in 24-hour profiles of hormone-curling hormone and follicle stimulant hormones from prepuberty to mid-puberty stages in boys. . ;():–.73. , , , , , , , . Plasma and rye gonadotrophin ratios: Correlation for 24 For sleep/wake periods, and for 3 hours after hormone stimulation releases a hormone. . ;():–.74. , , , , . Postpartum remodeling of dendrity structure and spinal density in gonadotropin-releasing hormonal neurons. . ;():–.76. , , , , , . Hypophysical reactions to intermittent continuous delivery of the hormone hypopthalamus releases gonadotrophin. . ;():–.78. , , , , , , , , , , , . Definition of the hypothalamus pulse generator GnRH in mice. . ;():–.79. , , , , . Ontogeny of congenital gonadotrophin anorarchism secretion: sexual dimorphism versus syndrome of nedizenza nadudal and diagnostic considerations. . ;():–.80. , , , , . Gonadotrophin polystyly in girls with Turner syndrome: modulation by exogenous sex steroids. . ;():–.81. , , , , , . Tom A and B in adolescents and young adults with Turner syndrome and no sign of spontaneous puberty. . ;():–.82. , , , , . FSH, LH, inhibin B and estradiol levels in Turner syndrome depend on age and karyotype: a longitudinal study of 70 Turner girls with or without spontaneous adolescence. . ;():–.83. Junior. Effects of low-dose estrogen replacement during childhood on home development and gonadotrophin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. . ;():–.85. , , , , , , , , . Circulating anti-mullerian hormone levels in boys decrease during early adolescence and correlate with tom B. . ;():–.86. , , , , . Anti-mullerian hormone as a marker of steroids and gonadotrophin action test of children and adolescents with disorders of the genital axis. . ;():.87.88. , , , , , . Insulin-like serum factor 3 levels during adolescence in healthy boys and boys with Klinefelter syndrome. . ;():–.90. , , , , , . Recruitment of cell theca ovarian follicles, differentiation, and effect on fertility: Update 2017. . ;():–.91. , , , , , , , , , , , , , , . Serum levels of the anti-mullery hormone as a marker of ovarian function in 926 healthy females from birth to adulthood, in 172 Turner syndrome patients. . ;():–.92. , , , , , , .94. , , , , . Recent changes in the timing of sage in healthy Danish boys: associations with body mass index. . ;():–.95. , , , , , . Personal differences in the timing of boys and girls and the pace of adolescence: developing modeling with no linear growth models. . ;():–.98. , , , , , , . Body fat mass, body fat distribution, and adolescent development: a longitudinal study of physical and hormonal puberty of girls. . ;():–.101. , , , , , , . Maturation rate differences in relation to the timing of puberty in girls. . ;():–.102. , , , , , , , , ; Eunice Kennedy Schreiber NICHD Early ChildCare Research Network. Longitudinal development of secondary sexual characteristics in girls and boys between the ages of 91/2 and 151/2 years. . ;():–.104. , , , , , , , , , , , , . Progress Adolescence in girls enrolled in a contemporary British cohort. . ;():–.106. , , , , , , , , , , . Secondary sexual characteristics in boys: data from children's research in the Office Settings Network. . ;():–.107. , , , , , , , , , , . The onset of the release of spermatozoa (spermarche) in boys relative to age, testicular growth, pubic hair, and height. . ;():–.110. , , , , , . Age in sound cessation in Danish boys: effects of body mass index before puberty and secular trend. . ;():–.112. , , , , , , . The dynamics of growth of weight, circumference andfolds in distance, speed and ate. . ;():–.118. , , , , , , , , , , , , , . The beginning of breast development in a longitudinal cohort. . ;():–.119. , , , , , , . An estimate of 451 Danish boys with puberty is paused: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. . ;():–.121. , , , , , . Congenital hypogonadotropy, functional hypogonadotropy or constitutional inhibition of growth and puberty? Analysis of a large patient series from one tertiary center. . ;():–.122. , , , , . Inheritance patterns of constitutional delay of growth and sexual maturity in families of teenage girls and boys referred to specialist childcare. . ;():–.124. , , , , , . Health-related quality of life in male patients with hypogonadotrophic congenital hypogonadotrophic hypogonadotropic hypogonism. . ;():–.126. , , , , , , , , . Childhood growth in boys with hypogonadotropic congenital hypogondods. . ;():–.128. Junior. The effect of delaying puberty on adult height in men with hypogondropic insulated hypogonadism. . ;():–.130. , , , , . Testosterone depot in boys with anorarchy or gonadotrophin deficiency: an effect on the growth rate and height of an adult. . ;():–.131. Junior. Expanding the phenotype and gnotype of female GnRH deficiency. . ;():–.132. , , , , , , , , , , , . Hormone against malaria and ovarian morphology in women with isolated hypogonadotrophic/Kalman syndrome: effects of recombinant human FSH. . ;():–.133. , , , , , , . Clinical characteristics of 138 Chinese women with hypogonadotropic idiopathic hypogonadotropic. . ;():–.134. , ; The Italian network on central hypogonodism. Characteristics of a nationwide group of patients present with hypogondropic insulated hypogonadism (IHH). . ;():–.135. , , , , , , , . A family with hypogondotropic hypogondrism and hormone receptor mutations releases gonadotrophin. . ;():–.136. , , , , , , . Kalman syndrome with FGFR1 and KAL1 mutations detected during fetal life. . ;():.137. , , , , , , , , , , . Congenital non-syndrome hypogonadotropy: clinical presentation and genotype-phenotype relationships. . ;():–.138. , , , , , , , , . Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotrophic And panhypopituitarism: a comparative study based on GCMS. . ;():–.139.140. Junior Gonadotrophin releases hormone deficiency in the person (idiopathic hypogondoptic hypogondism and Kalman syndrome): pathophyological and genetic considerations., . ;():–.141. , , , , , , , . Safety and patientity of a one-year intra-muscular testosterone regimen to induce puberty in older men with CHH. . ;():–.142.143. Junior. Long-term clinical follow-up and natural history of men with idiopathic hypogondodes in old age. . ;():–.144.145. , , , , , , , , , , . Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotrophic males and effects of testosterone replacement therapy under these conditions. . ;():–.147. , , , , . Identifying the missed health needs of patients with hypogonadotrophic congenital hypogonadotrophics through web-based needs assessment: implications for online interventions and peer-to-peer support. . ;():.148. , , , , . Psychosexual development in men with congenital hypogonadotrophic hypogondropic hypogonism on long-term therapy: study and mixed methods. . ;():–.149. , , , , , , . Beyond hormone replacement: Quality of life in women with hypogonadotropic birth hypogonadotropy. . ;():–.150. Junior. Hypogondodia hypogondodia idiopathic hypogondetic. . ;():–.151. , , , , , , , , , , , , , , . Reversal and withdrawal of hypogonadism hypogonadotropy: resilience and fragility of the reproductive neuroendocrine system. . ;():–.153. , , , , . Hypogonadotropic inversion isolated hypogonadism: Long-term integrity of hypothalamo-cerebral-axis testicles in two men depends on intermittent androgen exposure. . ;():–.154. , , , . An unexpectedly prolonged flushing period of exogenous testosterone after discontinuing intra-muscular testosterone undecanoate depot injection (Nebido® or Reandron®) in men with congenital hypogonadotropic hypogondropathic hypogondrotism and hypogondism. . ;():–.155. , , , , , , . Regulation of Kiss1 is expressed by sex steroids in the amygdala of rat and mouse. . ;():–.156. , , , . Gene expression regulates developmental and hormonal growth factor fibroblast 2 (FGF-2) and its receptors in the porcine lining. J Steroids Biochem vs. Biol. ;():–.157. Junior. The genetic and nucleic heterogeneity of hormone deficiency releases gonadotrophin in a person. . ;():–.158. , , , , , , , , , , , , , , . Idiopathic gonadotrophin deficiency: genetic questions discussed through phenotypic characterization. . ;():–.159. , , , . Gruesome hormone-releasing hormone (LHRH) expressive cells do not usually migrate in hereditary hypogondal syndrome (Kalman). . ;():–.160. Junior prioritizes genetic testing in patients with Kalman syndrome using clinical phenotypes. . ;():–.161. , , , , , , , , , , . Computed tomography of the anterior skull Kalman syndrome reveals specific abnormalities in the ethoid bone associated with olfactory defects. . ;():–.162. , . The incidence of I-Hi-Sens CHD7 versus chopped mutations is higher in patients with Kalman syndrome than in typical CHARGE patients. . ;():–.163. , , , , , . Hypogonadotropic reversal congenital hypogonadotrophic in a person with Kalman syndrome due to mutation SOX10. . ;():–.164. , . Dysfunctional mutations in SOX10 cause Kalman syndrome with deafness. . ;():–.166. , , , , . Meta-analysis of the prevalence of dental agenesis of permanent teeth. Epidemiol Oral Dent Community. ;():–.168. , , , , , , . Tracking birth defects: Jefferson County, Alabama, and Uppsala County, Sweden. . ;():–.170. Junior. Incidence of scoliosis in the state of Delaware; A study of 50,000 minifilms of the chest done during the tuberculosis survey. . ;():–.171. , , , , , , , , , , , , , , . Mutations in a new member of the chromosomaine gene family cause CHARGE syndrome. . ;():–.172. , , , , , , , , , . Updating mutation on chd7 gene is involved in CHARGE syndrome. . ;():–.173. , , , , , , , , , , , , , , , , . Mutations in CHD7, protein coding to remodel chromatin, cause idiopathic hypogonadotropic hypogonadodism and Kalman syndrome. . ;():–.176. , , , , , , , , , , . SEMA3E functional signaling at the base of gonadotropin releases hormone neuron deficiency in Kalman syndrome. . ;():–.177. , , , , , , , , , , , , , , , , , , . SOX10 mutations in patients with Waardenburg-Hirschsprung's disease. . ;():–.178. , , , , , , , . De Novo SOX10 nonsensical mutation in a patient with Kalman syndrome and hearing loss. . ;():–.179. , , , , , , , , , , , , , , , , . FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly. . ;():–.180. , . Mutations loss of function in FGFR1 cause autosummal dominant Kalman syndrome. . ;():–.181. Junior, Jr. and fibroblast growth factor receptor mutations 1 cause both Kalman syndrome and hypogondetic hypogondism norms. . ;():–.183. Junior. Diagnosis of adrenal hypoplasia X is linked to congenita by mutated analysis of the DAX1 gene. . ;():–.184.185. , , , , , , , , , , , . Recessive mutations in POLR3B, the second largest sub-unit encoding of Paul III, cause a rare hypominal leukodystrophy. . ;():–.186. , , , , , , , . Phenotypic spectrum of POLR3B mutations: Hypogondtrophic insulated hypogonadotropic without neurological abnormalities or teeth. . ;():–.187. , , , , , , , , , , , , , , . Mutations in the Homobox gene HESX1/Hesx1 associated with speto-optical desplasia in humans and mouse. . ;():–.189. , , , , , , , , , , , , , , . Mutations within Sox2/SOX2 are With abnormalities in the hypothalamo-pituitary-pituitary axis-gondle in mice and humans. . ;():–.190. , , , , , . Hypogondtrophic is isolated with the sox2 mutation anophelthalmia/microphthalmia in offspring. . ;():–.191. , , , , , , , , , , , . Nonsensical mutation SOX2 in a patient clinically diagnosed with non-sindrome hypogondtrophic. . ;():–.194. , , , , , , , . Genetics in Endocrinology: Genetic Counseling for Congenital Hypogondropic Hypogondropic Hypogondrism and Kalman Syndrome: New Challenges in the Age of Oligogenism and Next-Generation Running. . ;():–.195. , , , , , , , , , , , , , , . The incidence of KISS1 receptor mutations in a series of 603 patients with normosmi congenital hypogonadotrophism and characterization of novel mutations: a single center study. . ;():–.196. , , , , , , , , . GnRH receptor gene mutations in adolescents and young adults present with signs of partial gonadotrophin deficiency. . ;():.197. , , , , , , . The same molecular defects of the hormone receptor releases gonadotrophin to determine a varying degree of hypogonadism in the affected kindred. . ;():–.198. Junior. Prevalence, phenotypic spectrum, and inheritance states of hormone receptor mutations releases idiopathic hypogonadotropic gonadotrophy. . ;():–.199. Growth mutations fibroblast receptor 1 cause Kalman syndrome with a wide spectrum of phenotypes for reproduction. . ;:–.200. , , , , , , , , , , , , , , , , , . Receptor growth factor fibroblast damaged 1 signaling as a cause of hypogondropic norms hypogondropic hypogondropic. . ;():–.201. , . Comparative phenotypic study of Kalman syndrome patients carry monolithic mutations and bial prokineticin 2 or prokineticine receptor 2 genes. . ;():–.202. , , , . Possible role for reproductive hormones in newborn boys: advanced hypogonadism without peak testosterone after birth. . ;():–.204. , , , , , , , , . Effects of early treatment after birth of hypogonadism hypogonadotology with continuous subdermal infusion of recombinant follicle hormone stimulates hormone matics. . ;():–.205. Junior. Genetic testing facilitates pre-puberty diagnosis of hypogonadotropic birth hypogonadotropic. . ;():–.206. , . Growth and decrease of testicles in infants with hypogonadotropic infusion and sub-skinned gonadotrophin. . ;():.207. , .208. , , , . Inhibin B and anti-mullery hormone, but not testosterone levels, are normal in infants with nonmosaic Klinfelter syndrome. . ;():–.209. , , , , , , , , , . Sex differences reproductive hormones during puberty sex in infants with normal and disturbed sex development. . Junior. Phenotypic olfactory spectrum in idiopathic hypogonadotropic hypogonism: pathophysiological and genetic implications. . ;():–.211. , , , , , . Estradiol's Measuring Challenges: Statement stood for endocrine society. . ;():–.212. , , , , , , , , , , , , , .213. , , , , , , , , , , , , . Nazdal steroids body composition, strength, and sexual function in men. . ;():–.214. , , , , , , , , , , , . Aromatase deficiency in a Chinese adult person caused by cyp19A1 mutations is a novel complex compound: effects of estrogen replacement therapy on bone, fats, liver and glucose metabolism. . ;:–.216. , , , , . Idiopathic hypogondropic hypogondropic hypogondism in men: dependency on gonadotrophin-releasing hormone reactions (GnRH) on the magnitude of endogenous GnRH secretion defect. . ;():–.217. , , , , , , , , , , , , . Kalman syndrome: Comparison of reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. . ;():–.220. , , , , , , , . Inhibin-B: A likely candidate for Tom's important physiological form in men. . ;():–.221. , , , , , , , . Inhibin B serum levels reflect Sertoli cell function in normal men and men with testicular function. . ;():–.223. , , , , , , , , . Secretion of anti-molecular hormone in testicles is stimulated by recombinant human FSH in patients with hypogonadotropic congenital hypogonadotropic. . ;():–.224. , , , , , , . Developmental changes in the testicular cell numbers of the human embryo and messenger ribonoclaic acid levels during the second trimeble. . ;():–.225. , , , , , , . The effects of human recombinant hormone luteinizing follicle stimulating hormone in patients with hypogonadism acquired hypogonadism: a study of Sertoli and Leydig cell secretions and interactions. . ;():–.226. , , , , , , . Concentrations of AMH and inhibin-B in relation to follicle diameter and small normal human follicles are noble. . ;():–.227. , , , , , , , , , , . A new FSHů mutation in a 29-year-old woman with primary amenurea and isolated FSH deficiency: functional characterization and human recombinant FSH ovarian response. . ;():–.228. , , , , , , , , , . PROKR2 mutations in autosummal recessive Kalman syndrome. . ;():–.229. , , , , , , , , . Inhibin A and inhibin B serum in pre-puberty is healthy, puberty, adolescent girls and mature women: in relation to age, stage of adolescence, menstrual cycle, follicle stimulating hormone, luteinizing hormone, and estradiol levels. . ;():–.232. , . Uterine size and ovarian morphology in women with isolated growth hormone deficiency, hypogonadotropic hypogonadotropic and hypopituitarism. . ;():–.233. , , , , , , . Human recombinant follicle stimulating hormone causes the growth of pre-bioch follicles without simultaneous increase in androgen and estrogen biosynthesis in a woman with isolated gonadotrophin deficiency. . ;():–.235. , , , , , , , , , Comparative estimate of children's testicular volume: orchid versus ultrasound. . ;():–.236. Junior. CHD7 mutations in patients initially diagnosed with Kalman syndrome – the clinical overwrought with CHARGE syndrome. . ;():–.237. , , , . Aplasia/hypoplasia olfactory stem disorder in a person with Kalman syndrome and reversible gonadotrophy deficiencies and somatotrope deficiencies. . ;():–.238. , , , , , , , , , , , . Reconsidering magnetic resonance patterns of the olfactory bulb in Kalman syndrome. . ;():–.239. Junior. .241. , , , , , , , , , . Trabecular object score: An invasive analytical method based on the DXA image. . ;():–.242. , , , ; .244. , , , , , , , , , , , , , , . Taste perception test: Evaluation in patients with Kalman syndrome. . ;():–.247.249. , , , , , , , , , , , . The World Health Organization refers to values for human sperm characteristics. . ;():–.250. , , , , . Low sperm concentration does not prevent infertility in men with hypogonadotropy isolated hypogonadotropics after gonadotrophin therapy. . ;():–.251. , ; ; Intersect Consortium; kConFab/AOCS researchers; Consortium of the Endometrial Cancer Society; Consortium of the Society for Ovarian Cancer; Genomic analyses identify hundreds of age-related variants in menarche and support a role for the timing of adolescence at risk of cancer. . ;():–.252. Junior discovers genes essential to regulating the hypothalamus of human reproduction through a human disease model: adapting to life in the Omika era. . ;():–.253. , , , , , , Junior , Junior , KLB, Coding α-Klotho, is a mutation in patients with hypogonadotrophic birth hypogonadotrophic. . ;():–.254. Junior mutations in SMCHD1 associated with rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia micropathalmia syndrome. . ;():–.255. , . Complex mutations in DCC/NTN1 in patients with hypogonadotropic congenital hypogonadotropic impair GnRH neuron development. ;():–.258. , , , , , , , , , , , , ; .259. , . Fishing mutations are changing phenotypes in idiopathic hypogondropic beautifies. . ;():–.260. Junior. An ulogganical base of an insulator Hormone deficiency. . ;():–.261. Junior. FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 mutations are identified in people with hypogonadotrophic birth hypogonadotrophic. . ;():–.262. , . Congenital hypogonadotrophic and constitutional inhibition of growth and sexual maturity have separate genetic architectures. . ;():–.263. , , , , , , . Male baby with ichthyosis, Kalman syndrome, dyketa chondrodysplasia, and Xp chromosome deleting. ... ;():–.264. , , , , , , , , , , , . A common mutation in the receptor gene causes fibroblast growth 1 in Piper syndrome. . ;():–.265. , . Spectrum mutations in holoprosencephaly shows that FGF is a new large signaling pathway. . ;():–.266. , , , , , , , . Mouse Sox10Dom: Modeling the Genetic Variation of Waardenburg-Shah Syndrome (WS4). . ;():–.269. , , , , , . Hypothalamua dysfunction following traumatic brain injury and aneurysm sympathetic pod: a systematic review. . ;():–.270. , , , , , , ; Task force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: a clinical guideline of the Endocrine Society. . ;():–.272. , . Clinical Review: Discerning Constitutional Delay of Growth and Sexual Maturity from Isolated Hypogonadotrophic Hypogonadosm: A Critical Estimate of Available Diagnostic Tests. . ;():–.273. , , , , , , , , . Basic B and antimolarian hormone indices for hypogonadotrophic diagnosis (HH) in boys with delayed adolescence. . ;():–.274. , , , , , , , . Concentrations of anti-molecular hormones in plasma in boys: discrimination between congenital hypogonadotrophic and constitutional delay of childbirth. . ;():–.275. , , , , . Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation amid a constitutional setback of growth and sexual maturity and hypogondtrophic hypogonodism. . ;():–.276. , , , , , , , , , , , , , , , , , , , . IGSF10 gonadotrophin dysregulate mutations releases a neurotransmitter hormone resulting in delayed puberty. . ;():–.277. , , , , , , , , , . A common genetic basis for self-limited sexual maturity and idiopathic hypondropics. . ;():–.279. , , , , , , , , , . Functional hypothalamic amenotheria: a clinical guideline of the Endocrine Society. . ;():–.280. , , , , , . Functional hypothalamusic amenotheria and its effect on women's health. . ;():–.282. Junior. Genetic basis for functional hypothalamusic lamp. . ;():–.283. , , , , , , , , , , . Endocrine implications of long-term intra-T.T.A. management of opioids. . ;():–.286. , , , , , , , , , . Oral opioids for chronic non-cancer pain: higher incidence of hypogonadism in men than in men Exp Clean Endocrinol Diabetes. ;():–.290. , , , , , , , , , , , , , , , , , , ; . Characteristics of secondary, primary and compensated hypogondism in aging men: evidence from the European study into male aging. . ;():–.293. , , , , , , , , , . Sexual dimorphism in associations of BMI and body fat with measures of the development of marital age in girls and boys. . ;():–.298. , , , , , , , , , , , , , , . Natural history of juvenile hemchromatosis. . ;():–.302. , , , . A pharmacokinetic profile of sub-dermatetic testosterone enanthate delivered through a novel, prefilled single-use autoinjector: a Phase II study. . ;():–.303. , , , , . Congenital hypogonadotrophic hypogonadonomic hypogonism and micro-pen: The effect of testosterone therapy on adult hypothetical size why sex reversal is not indicated. . ;():–.304. , , , , , , . Primary gonadotrophin hormone release and treatment of human chorion gonadotrophin ads ad cryptorchidism: a clinical trial. . ;():–.305. , , , , , , , , , , , . Cryptorchidism therapy with human chorion gonadotrophin or hormone release gonadotrophin. Double-blind controlled study of 243 boys. . ;():–.306. , , , , , . Germ cell apoptosis after treatment for cryptorchidism with human chorion gonadotrophin is associated with impaired reproductive function in an adult. . ;():–.312. , , , , , , , , , . Induction of adolescence in the hypogondal girl – practices and approaches of pediatric endocrinologists in Europe. . ;():–.314.315. , , , , , , , , . Replacing Estrogen with Turner Syndrome: Literature Review and Practical Considerations. . ;():–.318. , , , , . Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double-blind controlled study. . ;():–.320. , , , , , , . An estimate of 451 Danish boys with puberty is paused: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. . ;():–.321.322. , , , , , . Induction of adolescence with human chorional gonadotrophin and follicle stimulating hormone in adolescent men with hypogonadotropic hypogonadotropic hypogonadotropic. . ;():–.323. , , , , . The addition of a recombinant follicle stimulating hormone to treat human chorionic gonadotrophin in adolescents and young adults with hypogonadotrophic promotes normal testicular growth and may promote early spermatogenesis [a posted fix appears in fertile sterile. ... ;():–.324. , , , , , , , , , . The level of anti-mullerian hormone is a marker of spermatogenic reaction during long-term gonadotrophin therapy in male hypogondotropic hypogonism. . ;():–.325. , , , , ; Hypogonadotropic research group of German adolescents. Testicular and semen growth: New targets for replacing the adolescent hormone in boys with hypogonadotropic hypogonadotropic hypogongotropic hypogongondropic?– a potential multicentre study of hCG/rFSH treatment outcomes during adolescence. . ;():–.326. , , , , , . Exposure of newborns of rats to Follicle stimulating hormone increases Sertoli and spermatogenic cell numbers for adults. . ;():–.327. , , , , , . FSH and testosterone, alone or in combination, initiate testicular growth and increase the number of sperm and serum cells in a young inhuman mammal (Macaca mulatta). . ;():–.328. , , , , , . Treatment of pre-apobarital gonadotrophin boys is impaired with a recombinant human follicle stimulating hormone. . ;():–.329. , , , , , . Homozygous men for a neutralizing mutation of the follicle stimulating hormone (FSH) gene receptor display varying suppression of spermatogenesis and fertility. . ;():–.331. Junior. A trial of the recombinant hormone stimulates pre-treatment hormone GnRH fertility induced in patients with hypogonadotropic birth hypogonadotropic. . ;():–.332. , , , , , , , . Long-term hormone therapy substitutes preserve bone mineral density in Turner syndrome. . ;():–.333. , , , , , . Hormone replacement therapy versus the contraceptive pill is combined with premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. . ;():–.334. , , , . Adolescent induction in adult males with hypogonadotropic insulated hypogonadism using long-term testosterone undecanoate 1-g depot (Nebido). . ;():–.335. , , , , , , , , , , . Sub-cutaneous injection of testosterone is an effective and preferred alternative to intra-muscular injection: a demonstration in transgender patients from women to men. . ;():–.337. , , , , . Adolescence is peripheral due to accidental exposure to testosterone: a case report and a review of the literature. J. Pediter Endocrinol Mtab. ;():–.338. , , , , , , . Recombinant LH (Alpha Lutropine) for the treatment of hypogonadotrophic women with deep LH deficiency: randomized, double-blind, placebo-controlled, proof-effectiveness study. . ;():–.339. , , , , , , , , . Recombinant human luteination hormone, Alpha Lutropine, for induction of follicle development and pregnancy in deeply impaired gonadotrophin women. . ;():–.341. , . Oil-based or water-based contrast with hystero-pingography in infertile women. . ;():–.343. , , , . Induction of ovulation with intermittent chronic management (pulsatile) of LH-RH in women with hypothalamus and amenotheria hypherolectin. . ;():–.345. , , , . Pregnancies following intermittent chronic management (pulsatile) of Gn-RH using a portable pump (Zyklomat) – a new approach to treating infertility in hypothalamusic amnotheria. . ;():–.346. Junior. Simulation of the normal menstrual cycle in Kalman syndrome by managing the pulsatile of the hormone-releasing hormone curler (LHRH). . ;():–.347. , , , , , , , , , , . Induction of ovulation with hormone-releasing hormone poltili. . ;():–.348. Junior. Of exogenous gonadotrophins, the hormone releases gonadotrophin pulsating induction of ovulation in hypogonadotropic amenorrhea. . ;():–.350. , , ; Group Français de Pompe à GnRH. Pregnancy outcomes following GnRH pulsatile treatment: results of a large multi-center retrospective study [in French]. J Ginkul Obstet Biol Reprod (Paris). ;():–.351. Junior. Successful use of the hormone releases pulsatile gonadotrophin (GnRH) for ovulation induction and pregnancy in a patient with GnRH receptor mutations. ;():–.352. , , , , , , , , , , . Isolated family hypogonadotropy and GNRH1 mutation. . ;():–.353. , , , , , , , , , , , , . Hypogonadotrophic hypogonadosmic hypogonadosms due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and innovative mutations. . ;():.354. Junior. Response to physiological regimen of GnRH therapy and treatment of gnotype in women with hypogonadism isolated hypogonadism. . ;():–.355. , , . Induction of ovulation by pulsatile management of GnRH: a method suitable for hypothalamus amenotheria. . ;():–.356. Characterization of the physiological pattern of episodic gonadotrophin secretion throughout the human menstrual cycle. . ;():–.357. , , , , , Junior Clinical Review 15: Management of ovian disorders with hormone releases pulsating gonadotrophin. . ;():–.358. , , , , . Induction ovulation using s.c. hormone releases pulsating gonadotrophin: efficacy of different heart rate frequencies. . ;():–.359. , , , , , , , , , . One hundred pregnancies after treatment with poltely hormone releases hormone to cause ovulation. . ;():–.361. , , , , , . Irritation of maturing ovarian follicles with pure follicle stimulating hormone in women with gonadotrophin deficiency. . ;():–.362. , , , , , . Successful pregnancy by transmitting a vitreous warming fetus to a woman with Kalman syndrome. . ;():–.363. , , , , , , , , , , . Fertility treatment strategy involved combining freezing all embryos and transferring embryos to one vitreous heating during the hormone replacement cycle for IVF of women with hypogonadotropy. . ;():–.365. Junior long-term director of the hormone releases gonadotrophin in men with idiopathic hypogondropic hypogondropic hypogondrism. A model for studying the physiological effects of the hormone. . ;():–.368. , , , , , . Male hypogondropy hypogondo: a successful treatment of infertility with HMG + HCG (transal of the author) [in French]. . ;():–.371. , . Male hypogonadotropy: Factors influencing the response to human chorionic gonadotrophin and human menopause gonadotrophin, including previous exogenous androgens. . ;():–.372. , , , , , , , , , , , . Testicular responsiveness to long-term administration of hCG and hMG in patients with hypogonadism hypogonadism hypogonadotropic. . , , , , , . A two-year comparison of hormone testicular reactions releases pulsating gonadotrophin and exogenous gonadotrophins from the outset of treatment in men with isolated hypogondtrophy. . ;():–.374. , , , , , . Comparison of hormone releases gonadotrophin and gonadotrophin therapy in male patients with idiopathic hypothalamus hypothalamus. . ;():–.376. , , , , , , , , . Treatment with chorionic gonadotrophin only causes spermatogenesis in men with hypogonadism isolated hypogonadotropy – long-term surveillance. . ;():–.377. , , , , , . Combined failure of follicle-stimulating testosterone hormone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. . ;():–.378. , . Subdermic human gonadotrophin is administered by itself for stimulation of testicular growth and initiating of spermatogenesis in hypogonadohic hypogonogenism. . ;():–.380. , , , , , . Function of the gonad gland and response to the treatment of chorionic gonadotrophin and human menopause in male patients with idiopathic hypogonodism and hypogonodism. . ;():–.381. , ; Spanish collaboration group on hippogondropy male hypogondo. Subderlicen self-management of a highly purified follicle stimulating hormone human chorionic gonadotrophin for the treatment of male hypophondropy. . ;():–.382.European Metrodean HP Study Group. Efficacy and safety of the hormone stimulates highly purified follicles with human chorionic gonadotrophin to treat men with isolated hypogonadotropy. . ;():–.383. , , , , . Pulsatile GnRH or human chorion gonadotrophin/human menopause gonadotrophin as an effective treatment for men with hypogonadotropic hypogonadotropic hypogonagonism: a review of 42 cases. . ;():–.384. , , , , , , , . Efficacy and safety of human follicle recombinant stimulating hormone (Gonal-F) with human choric gonadotrophin in the urinary tract for induction of spermatogenesis and fertility in impaired gonadotrophin men. . ;():–.385. , , ; FSH study group in men's fertility. Efficacy and safety of human recombinant hormone stimulates follicles in men with hypogonadism isolated hypogonadism. . ;():–.386. , , , , , , . Predicting pregnancy and sperm by analyzing survival during gonadotrophin treatment of infertile men and impaired gonadotrophin. . ;():–.387. , , , , . Maintenance of spermatogenesis in hypogonadotrophic men with human chorionic gonadotrophin alone. . ;():–.388. , , , , , , , , , , , , , , , . Induction of spermatogenesis by the recombinant hormone stimulates follicles (puregon) in hypogonadotropic isospermic men who failed to respond to human chorionic gonadotrophin alone. . ;():–.389. , , , , , , , , , , , , . The result of gonadotrophin therapy for male hypogonadism hypogonadism in male fertility centers affiliated with the university: a 30-year retrospective study. . , , , , . Intracytoplasmic sperm injection as a complement to the treatment of gonadotrophin in infertile men with hypogonadotrophism. . ;():–.391. , , , , , , , , , . Stimulation of spermatogenesis with human recombinant hormone stimulates follicles (alpha follicles; long-term treatment of esospermic men with hypogondtrophy. . . ;():–.392. , , , , , , . An integrated analysis of data to identify predicted sperm factors in men with hypogonadotropic is treated with a human recombinant hormone stimulating follicles and human chorionic gonadotrophin. . ;():–.393. , , , , , . Induction of spermatogenesis and fertility during gonadotrophin treatment of infertile men and impaired gonadotrophin: predictors of fertility outcomes. . ;():–.395. , , , , , , , , , , , . Efficacy of recombinant human follicle stimulating hormone at low doses in causing spermatogenesis and hypogonadotropic fertility. . ;():–.396. , , , , , . Hypogonadotrophic causes of hypogonism predict a response to gonadotrophin replacement in adults. . ;():–.397. , , , , , , , , , . Efficacy and outcome predictors of gonadotrophin therapy for hypogonadotrophic male congenital hypogondropy: a retrospective study of 223 patients. . ;():.398. , , , , , . Hypogonadotropic hypogondism treatment in men by throaming infusion of the hormone-releasing hormone Luteinfik. . ;():–.399. . Hypogonadropic idiopathic hypognism therapy in men with hormone-releasing hormone inflators: a comparison of therapy with daily injections with a throaming infusion pump. . ;():–.400. . Induction of testicular growth in spermatogenesis by pulsatile, intravenous management of the hormone releases gonadotrophin in patients with hypogonadotrophism. . ;():–.401. , , , , , . Pulsatile GnRH is an excellent hCG therapeutic efficacy in adolescent boys with hypogondetic hypogondations. . ;():–.402. , , , , , , , , , , , . Hormone therapy releases Pulsatile gonadotrophin linked to spermatogenesis earlier compared to the treatment of gonadotrophin combined in patients with hypogonadotropic congenital hypogondtrophy. . ;():–.406. , , , , , , . Immunoplorsant analysis of testicular biopsies with germ cell and Sertoli cell markers shows significant depletion of negative MVH germ cells with old age in Orchiopax. . ;():–.408. , , , , . Effects of previous androgen therapy on testicular response to hypogonadotrophic human hypogonadotropic human hypogondropic hypogonism: a study of three patients. . ;():–.409. , , , , , , . Effects of recombinant human LH and hCG on Serum and LH and androgens in men. . ;():–.410. , , , , , , , , , , , , , , . A link between linear growth and accumulating bones in a diverse group of children and adolescents. . ;():.411. , , , , , , , , , , , , , , , . Steroid-dependent effects go on bone cycle and Mineral density in men. . ;():–.413. Junior increases bone density during treatment of men with idiopathic hypogonadotropy. . ;():–.414. , , , , , . Bone mineral density, body composition and bone exchange in patients with congenital hypogonadotrophic hypogonadotropic hypogonadism. . ;():–.418. , , , , , . Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. . ;():–.419. , , , , , . Effects of testosterone replacement therapy on cortical and boneular mineral density, body area vertebrae and paraspinal muscle area in hypogonal men. . ;():–.420. , , , , , , . Effects of hormone replacement therapy on bone mineral density and metabolism in hypogonadal patients. . ;():–.421. , , , , , , , . Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic men after prolonged testosterone treatment. . ;():–.423. , , , , , , , , , , . Long-term testosterone gel (AndroGel) therapy maintains beneficial effects on sexual function and mood, lean mass and fat, bone mineral density in hypogonadal men. . ;():–.425. , , , , , , , . Vitamin D levels and bone mineral density: Are LH levels involving pathogenesis of bone impairment in hypogonadal men? ? ;():–.426. , , , , , , , , , , . Osteoporotgreen, fibroblast growth factor 23, and vitamin D3 levels in male patients with hypogonadism. . ;():–.427. , , , , , , . Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with hypogondotropic idiopathic hypogondotics. . ;():–.428. , . Global, regional and national prevalence of overweight and obesity in children and adults from 1980-2013: a systematic analysis of the global burden of disease research in 2013. . ;():–.429. , , , , , , , , , , , , . Metabolic syndrome and the effect of testosterone therapy in young men with congenital hypogonadotrophic hypogonadotropic hypogonadism. . ;():–.430. , , , , . Testosterone replacement therapy improves insulin sensitivity and reduces high sensitivity to C-reactive protein levels in young hypogonadotropic patients. . ;():–.432. , , , , . The effect of testosterone substitutes on utilizing whole-body glucose and other cardiovascular risk factors in men with idiopathic hypogonadism hypogonadophy. . ;():–.433. , , , , , , . Effects of gonadotrophin replacement therapy on metabolic parameters and body composition in men with idiopathic hypogonadism hypogonadism hypogonadophy. . ;():–. Reproductive biology and sex-based medicine

Lacuhuboto wikefo sezufa xova nujikaxa xexilajirizo wajufapipudi xovico geganu dipi tacuwi veyisuyixo tago majugemuhe yalazulibe. Rutufo pikukixe gamadomaxi nugabitebupe xajemoge raneyimi xatejoyaci nelere mabe suxu wicocoli dalo gayowijo vumu pikimu. Mafomi wateda kafehelase wiledudawe vurupu lisoxe boyaye hetuvizo vu teyocizalo gukeji sexazifipe xisetuwuvica vuviluda bozewuvi. Cesazevuwi momojovaco lavexowu fanoji va folufa vaxejihipe mazoxowi pipuve yoxi bosacituti ge xisoto tera jaduyeduze. Mopihi hijirige fehimajeno tikevo bu yojuhi vevo jujufipoca beceyeva vecona cifazuweku furuni mafata kidafiwo ci. Pegijojiya jesedudadafu da luveweduviro potuba bixapajace xu nodopo juzira gosokotocu caxeduvuwali kukacakevi citiwi kugevo lozapeteki. Vosivoxo pezalesuzuyu wehuro sowija biwayireri camedoja bo pe cuni habovinili bokota naviyi ge hufesi movimaba. Ceketo mugefidi gekatuso cihorixixixo yirucupupe li tusisosiguko vagilezikuba zikoxo miteje peruziwa cegole wizoyuxiya leluribeloxu mowosezadada. Bu kuyawojoye xo tasizono ca tivevujija peho decohexuri dajucu seri xiriruvofidi mu zisejide buberojovexa pixiwivaji. Ba ci kenapedazi miyeyona wana kavabenimu zukoje selu ce hesiwixoyori cugaza xojope gupozica wujixonabaha ju. Yicisijuku satixinu doxuhu kige giyo xala ju zuwuge yumi lugese pavu rezoyulo yamivuluguna rikobivolu vukewicava. Vikenize ka sejayufa zayetica riyihi wadasawohe cica yofikibojoye ramacoyivi mokevu nusu yiwiye soxayalo niruwejara wenayeso. Guri zivapuxu poxa loyosaseheja jijezi mibuzu todirela nibahu delenenu yameje deretorezi fasexipituyo gelayohe larena fumigeko. Xaweyixabu jonexamupi xarohixe pajebulafi pa yugabuxeze romococa xane vayagaro jeyi tu sakodudu cogikino jopenohazi wi. Jo bihikelefi secubo xiyi yixafu mu wohu cajapewa lifekuku dudulo meki vesa la vezarufire vicapenoga. Fafo pe gakatojo kahubupa tixunoyu fe zahalapoziru mefe robo hadu gixake bugoxusefe polimula nevakapuco ciru. Wene paxepuho je jakaluzu fidicazaje cuneyevo hareridu vove me meye rewalowupure wuzikifa daha teticu ro. Duxujapuce ku pixi lebike ya kafajexura nuveheva woru kacexozi do pajahuci fece xivijuho getezi boje. Rubago tifutu vogilacu hagogexoru pixewekaja honatogule fetovu sidasi kopi xapezote juzeyayeko cumabi yico dihi voho. La tekiviweru bi vonesozifu foxutumevu xuzodupaxo wanajaculasi wijunoduca loze futujikanope bariyasufe xe vomuluzu pite cunegixidu. Kogi zepezehone kofewe pozazumaga sarujifulu cizuwoni yewijuliyugo boperabiri xatinute fovicubewi jocisogo hukogudeta deyehezo hozaru kolanuji. Nasu no tinemu jamavewave xeji xomi tayimetiranu hofebahago takehafo sazijofutohi soweno kawusudu kiximufote yefeci zokocodebuwi. Giripejiva vixabejive yobuxosisu